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 O cancro do pâncreas é, presentemente, uma das áreas de estudo mais desafiantes da 
Oncobiologia. O diagnóstico tardio, juntamente com a falta de conhecimento do processo de 
carcinogénese a nível molecular, torna esta patologia uma das mais mortais em todo o mundo, 
sendo a taxa de mortalidade praticamente equivalente à taxa de incidência. Um maior 
conhecimento sobre o processo de carcinogénese pancreática que permita um diagnóstico 
precoce e o desenvolvimento de terapias mais eficazes é crucial.  
 A mucina MUC1 é uma glicoproteína transmembranar normalmente expressa na região 
apical das células epiteliais com uma grande relevância na proteção e lubrificação dos 
epitélios, na interação célula-célula e célula-matriz, assim como na sinalização celular. Nos 
tumores epiteliais, como o cancro do pâncreas, sabe-se que esta molécula está sobrexpressa 
e aberrantemente glicosilada. 
O objetivo deste trabalho foi compreender o envolvimento do MUC1 na biologia das 
células estaminais tumorais e desvendar a contribuição das variantes de splicing alternativo 
para a carcinogénese do pâncreas, duas áreas científicas pouco exploradas.   
A glicoproteína membranar designada de prominin-1 (CD133) foi inicialmente descrita 
como sendo um antigénio específico das células estaminais hematopoiéticas e células 
progenitoras e apesar da sua função biológica permanecer pouco conhecida é, atualmente, 
usada na identificação e isolamento das células estaminais tumorais em alguns tipos de 
cancro, incluindo o pancreático. Recorrendo a modelos in vitro e in vivo foi avaliado o 
envolvimento da proteína MUC1 nas vias de sinalização de uma subpopulação celular 
altamente tumorigénica, que expressa CD133 e se designa de CD133+. Os nossos resultados 
sugerem que as células CD133+ expressam níveis mais elevados de MUC1, contribuindo para 
o fenótipo tumorigénico destas células através da interação entre o domínio citoplasmático do 
MUC1 e a proteína β-catenina, que por sua vez modula cascatas de sinalização oncogénicas. 
Apesar da maioria dos esforços até agora estarem centrados essencialmente no estudo 
da proteína completa do MUC1, o gene MUC1, tal como cerca de 95% de todos os genes 
humanos com mais que um exão, sofre processos de splicing alternativo. Sabe-se que este 
processo tem funções chave na regulação e expressão génica contribuindo para a 
heterogeneidade do transcriptoma e do proteoma celular. Foram identificadas até à data mais 
de 70 variantes de splicing do MUC1, no entanto, a relevância biológica destas isoformas 
continua por esclarecer. De forma a contribuir para o esclarecimento das suas funções 
biológicas e considerando as ferramentas disponíveis, foi usado um modelo de células 
pancreáticas in vitro com expressão da variante de splicing MUC1/S2. Foi possível observar 
que a expressão da isoforma MUC1/S2 é mais restrita ao citoplasma e leva a um aumento da 
capacidade de invasão das células geradas. Curiosamente, identificamos pela primeira vez a 
interação entre a isoforma MUC1/S2 e a proteína p53, o que nos pode indicar um papel desta 
isoforma em vias de sinalização oncogénicas. Por último, destacamos os avanços científicos 
xx 
 
na área do MUC1 relativos aos dois principais temas enfatizados neste trabalho, salientando 
pontos de futuro interesse nesta área de investigação. 
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Pancreatic cancer is nowadays one of the most challenging fields of the oncobiology 
scientific community. Late diagnosis together with the lack of a better understanding of the 
carcinogenic process make this pathology one of the most lethal worldwide, with almost 
identical incidence and mortality rates. An improvement in basic scientific knowledge of the 
pancreatic carcinogenesis to allow earlier diagnosis and improved therapies remain unmet 
needs for this disease. 
MUC1 is a transmembrane glycoprotein generally expressed in the apical surface of 
epithelial cells with an important role in protection and lubrification of the epithelium’s, in cell-
cell/cell-extracellular matrix interaction and in signaling transduction. In epithelial cancers, 
namely in pancreatic cancer, this molecule is known to be overexpressed and aberrantly 
glycosylated. 
The aim of this work was to understand the involvement of MUC1 in cancer stem cell 
biology and to disclose the contribution of MUC1 splice variants in pancreatic carcinogenesis, 
two unexplored scientific topics. 
The pentaspan membrane glycoprotein prominin-1 (CD133) was initially described as a 
cell surface antigen specific of hematopoietic stem and progenitor cells and despite its 
biological function remaining unclear it is currently used in the identification and isolation of 
cancer stem cells from some malignant tumors, including pancreatic cancer. Using in vitro and 
in vivo models, the involvement of MUC1 in the signaling pathways of a highly tumorigenic 
CD133+ cellular subpopulation was evaluated. The results suggest that CD133+ cells have 
higher MUC1 expression, contributing to the tumorigenic phenotype through increased 
interaction between MUC1-CD and β-catenin, which in turn modulates oncogenic signaling 
cascades. 
Although most efforts so far were focused on the full MUC1 protein, the MUC1 gene, like 
more than 95% of all multiple-exon human genes, undergoes alternative splicing events. This 
is a key process in the regulation of gene expression, contributing to the heterogeneity of the 
transcriptome and the proteome. MUC1 has more than 70 different splice variants identified 
yet their biological function remains to be elucidated. In order to provide insights into their 
biological function and taking into account the available tools, we used a pancreatic in vitro 
model transduced, using a lentivirus system, with MUC1/S2 splice variant and characterized 
its phenotype. It was possible to observe that MUC1/S2 expression is mostly restricted to the 
cytoplasm and leads to an increase in the invasive phenotype of these cells. Interestingly, an 
interaction between MUC1/S2 and p53 protein was identified for the first time, which can 
indicate a role of this isoform in signaling pathways. Finally, scientific advances in MUC1 
research concerning the two topics emphasized in this work were highlighted, raising future 
points of interest in this research area. 
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             Cancer epidemiology 
 
Cancer is a major concern in public health and despite the efforts to improve prevention, 
diagnosis and treatment, the incidence is expected to grow, mostly due to the growth and aging 
of the world population and the increasing prevalence of established risk factors worldwide 
(Torre et al. 2015). In 2012, 14.1 million new cases and 8.2 million cancer-related deaths were 
estimated by GLOBOCAN, through the International Agency for Research on Cancer (IARC) 
(Ferlay et al. 2015). Cancer epidemiology is different between developed and developing 
countries where lung cancer is the most incident and leading cancer death among males while 
breast cancer represents the most incident and lethal neoplasia among females. In developed 
countries, although lung cancer leads mortality rates, prostate and breast cancer are the most 
incident, respectively, among males and females. In Europe, prostate, breast, lung, colorectal, 
and stomach cancers are the most frequently diagnosed (Ferlay et al. 2013). 
 
    Pancreatic cancer 
Epidemiology and risk factors 
 
Pancreatic cancer (PC) is one of the most lethal cancers being the seventh leading cause 
of cancer-related deaths worldwide, for both sexes. Data from GLOBOCAN estimate that 
338,000 individuals have been diagnosed with PC in 2012, being 104,000 of these new cases 
diagnosed in Europe. In Europe, pancreatic cancer represents the fifth leading cancer death 
among males and the fourth among females being 30% more common in men than in women 
(Ferlay et al. 2013, ACC 2014, Ferlay et al. 2015). 
The major concern related with this neoplasia is that incidence rates are almost identical 
to mortality rates, which is reflected in a five-year survival of only 6%, and with almost no 
changes achieved in the last decades, it has the poorest prognosis of any major tumor type. 
The incidence and mortality rates of pancreatic cancer are higher in developed countries 
and the numbers have been increasing over the past years, mostly due to the influence of risk 
factors. PC risk factors encompass demographic, lifestyle and environmental factors as well 
as multiple genetic syndromes. Overall, according to the National Cancer Institute (NCI), these 
risk factors and genetic syndromes are responsible for 30-40% of all pancreatic cancers (ACC 
2014). 
One of the most reliable and important risk factors in PC, as for most cancer types in 
adults, is age. The median age of diagnosis is 71 years old with 53% of the cases diagnosed 
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between 65 and 84 years old and only 3% under age 44 (ACC 2014). Ethnicity is also 
accountable for PC incidence/mortality being African-Americans more likely to be diagnosed 
with advanced disease than any other race or ethnic group (Chang et al. 2005). 
Cigarette smoking is another well-established risk factor in PC development identified as 
a causative agent in case-control, cohort and retrospective studies (Lowenfels et al. 2001, 
Lynch et al. 2009, Bosetti et al. 2012). The risk of developing PC in cigarette smokers is around 
2.2-fold higher and it has been estimated that 15-20 years of smoking cessation is necessary 
to achieve a similar risk to non-smokers (Boyle et al. 1996, Lowenfels et al. 2001, Bosetti et al. 
2012). Smoking is particularly harmful in patients with Helicobacter pylori (HP) infection and 
familial pancreatic cancer (FPC) where it can result in a 2-fold and a 4-fold increased risk, 
respectively (Lowenfels et al. 2001, Rulyak et al. 2003, Klein et al. 2004). 
In a dose-dependent relationship, heavy alcohol usage (three or more drinks per day) is 
also associated with a 1.22 to 1.36-fold increased risk of PC development, possibly through 
pancreatitis induction (Genkinger et al. 2009, Tramacere et al. 2010, Yeo and Lowenfels 2012). 
Diet and obesity are other lifestyle risk factors that increase the likelihood of developing 
PC. Butter, saturated fats, red meat and processed food consumption increases the risk of PC 
independently of their role in obesity while fruit and vegetables are associated with a protective 
effect (Stolzenberg-Solomon et al. 2001, Larsson and Wolk 2012). Body mass index (BMI) of 
over 40 is associated with a relative risk of PC of 1.49 for men and 2.76 for women (Calle et 
al. 2003). Moreover, obesity was associated with a younger age of onset, late-stage at time of 
diagnosis and decreased survival rates (Stocks et al. 2009, Yuan et al. 2013). The role of 
obesity and diet in development of PC may include abnormal glucose metabolism, 
hyperinsulinemia, inflammatory changes and pancreatic hypertrophy and hypoplasia as a 
response to cholecystokinin-mediated lipase secretion (Gapstur et al. 2000, Stolzenberg-
Solomon et al. 2005, Stattin et al. 2007, Stocks et al. 2009, Jarosz et al. 2012). 
Pancreatitis can be a cause or consequence of PC and has been widely studied as a risk 
factor in the development of this neoplasia. Chronic pancreatitis, characterized as inflammation 
of the pancreas that increases over time and leads to permanent morphological changes, is 
considered a well-established risk factor and represents a relative risk of 13.3 for PC 
development. Pancreatitis occurring less than 2 years prior to cancer diagnosis is associated 
with a higher risk (odds ratio (OR) =13.6, 95% CI = 8.7– 22) however, it is not well established 
whether in this case pancreatitis precedes cancer or is a consequence of pancreatic ductal 
obstruction from the tumor mass (Raimondi et al. 2010, Duell et al. 2012). Chronic pancreatitis 
explains around 3% of all PC cases and the most common cause of chronic pancreatitis in 
developed countries is alcohol abuse (around 60%-90%) and less commonly hereditary and 
autoimmune pancreatitis (Lowenfels et al. 1999, Pandol and Raraty 2007). 
   Chapter 1 | General Introduction 
3 
 
Over the past 40 years, multiple studies have correlated PC and diabetes mellitus leading 
to the postulation that type 2 diabetes is the third most modifiable risk factor in the development 
of this neoplasia, after cigarette smoking and obesity (Li 2012). Type 2 diabetes represents an 
overall OR of 1.8 (95% CI=1.5-2.1) when compared with non-diabetics. However, this 
correlation is complex since long-term disease is associated with a decrease in PC relative 
risk when compared to PC patients that only develop diabetes 1-3 years before diagnosis 
(OR=2.9, 95% CI=2.1–3.9) which can indicate diabetes as an early manifestation of PC (Chari 
et al. 2005, Cui and Andersen 2012). 
Occupational exposure to toxic and carcinogenic material such as chlorinated 
hydrocarbon (CHC), nickel and nickel compounds, polycyclic aromatic hydrocarbons (PAH), 
among others, are appointed to contribute to about 5% of all PC cases (Ojajarvi et al. 2000, 
Lowenfels and Maisonneuve 2004). 
Despite more than 80% of all PC being due to sporadic mutations, inherited genetic 
changes can be an important risk factor for PC. Case-control and cohort studies demonstrated 
that family history can increase the risk of PC in a range of 1.9 to 13-fold, being involved in 
approximately 5-10% of all cases (Falk et al. 1988, Ghadirian et al. 1991, Price et al. 1996, 
Breast Cancer Linkage 1999, Schenk et al. 2001, Jacobs et al. 2010). Familial PC is defined 
when at least two first-degree relatives are affected and the relative risk is directly related with 
the kinship and the number of affected family members (Klein et al. 2004, Wang et al. 2007, 
Wang et al. 2009, Brune et al. 2010). Furthermore, familial PC is also associated to an 
increased risk of breast (1.6-fold, 95% CI=1.15-2.34), ovarian (2.05-fold, 95% CI=1.10-3.49) 
and bile duct cancer (2.89-fold, 95% CI=1.04-6.39) (Wang et al. 2009). Germline BRCA2 
mutations are the most commonly inherited genetic alterations associated with this neoplasia 
(Tersmette et al. 2001, Murphy et al. 2002). Different studies have found BRCA2 mutations in 
17-19% of familial PC families (Goggins et al. 1996, Breast Cancer Linkage 1999, Murphy et 
al. 2002, Hahn et al. 2003). Other germline mutations have also been related with an increased 
risk of PC such as mutations in PALB2, BRCA1 and p16/CDKN2A genes (Moskaluk et al. 
1998, Thompson et al. 2002, Rutter et al. 2004, Axilbund et al. 2009, Ferrone et al. 2009, 
Tischkowitz et al. 2009, Slater et al. 2010, McWilliams et al. 2011). Several germline genetic 
syndromes have also been associated with genetic predisposition to PC and altogether 
account for less than 20% of all familial PC (Murphy et al. 2002, Hruban et al. 2010). Hereditary 
pancreatitis, familial atypical multiple mole melanoma syndrome (FAMMM), Lynch syndrome, 
familial adenomatous polyposis (FAP), hereditary breast and ovarian cancer syndrome, cystic 
fibrosis, Peutz-Jeghers syndrome, Li-Fraumeni syndrome, ataxia-telangiectasia, Fanconi 
anemia and more recently Non-O blood groups are the syndromes that are documented to 
have an involvement in the development of this neoplasia (Giardiello et al. 1993, Goggins et 
al. 1996, Moskaluk et al. 1998, Breast Cancer Linkage 1999, Borg et al. 2000, Giardiello et al. 
Chapter 1 | General Introduction   
4 
 
2000, Murphy et al. 2002, Hahn et al. 2003, Amundadottir et al. 2009, Kastrinos et al. 2009, 
Egawa et al. 2013). 
The identification of risk factors, whether genetic or lifestyle related, can have a huge 
impact in PC incidence as a result of population behavior as well as in early diagnosis and 
treatment through the identification of the high-risk population that can benefit from preventive 
strategies. 
 
Pancreas overview 
Pancreas is a complex and highly branched gland, playing a crucial function in secretion 
of digestive enzymes and in glucose homeostasis. Along with the liver and biliary tract, the 
pancreas arises from a shared multipotent population of cells in the foregut endoderm, is 
located deeply in the retroperitoneum, behind the stomach, and is anatomically divided in four 
different parts: head, neck, body and tail. Histologically, pancreas is divided in endocrine and 
exocrine portions (Lack 2003, Wandzioch and Zaret 2009) (Figure 1). 
The endocrine portion accounts for around 2% of the pancreas, encompasses the islets 
of Langerhans, and is responsible for secretion of hormones into the bloodstream. The Islets 
of Langerhans embrace different specialized cell types, each one responsible for the 
production of a different hormone and are densely vascularized and surrounded by acini cells. 
Beta (β) cells, that represent around 60% of the islet cells, are responsible for insulin production 
while alpha (α) cells secrete glucagon and represent around 30% of the islet cell population 
(Slack 1995). Somatostatin, secreted by Delta (δ) cells, is a potent inhibitor of insulin and 
glucagon secretion and accounts for less than 10% of the islet cells (Sakurai et al. 1974, Luft 
et al. 1978). Together, these three types of specialized cells are responsible for glucose 
homeostasis into the bloodstream by endocrine and paracrine regulation. Contrary to what 
happens in other animals, like rodents, recent studies showed no clustering of β cells in islets. 
In these studies, it was possible to observe that β cells are scattered throughout human islets 
with the other endocrine cells aligned along blood vessels with no particular order or 
arrangement (Brissova et al. 2005, Cabrera et al. 2006). Nonetheless, controversies persist 
about the architectural arrangement of pancreatic endocrine cells (Orci and Unger 1975, 
Erlandsen et al. 1976, Orci 1976, Bosco et al. 2010). Pancreatic polypeptide (PP) producing 
cells represent less than 5% of the islet cells and the peptides are released by vagal stimulation 
and, although the physiologic role remains to be clearly established, it is known to be involved 
in satiety sensation after food intake (Larsson et al. 1976, Asakawa et al. 1999, Batterham et 
al. 2003). More recently, some studies appointed the existence of a different type of cells in 
the endocrine pancreas, the ghrelin-producing cells, that are believed to be involved in the 
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control of insulin secretion, metabolic regulation and energy balance (Lee et al. 2002, Wierup 
et al. 2002, Wierup et al. 2004). The islets of Langerhans are distributed within the exocrine 
pancreas, which emphasizes its important physiological function in the modulation of the 
exocrine function and homeostasis (Barreto et al. 2010). 
Exocrine pancreas represents nearly 95% of all pancreatic mass, being mainly composed 
by acinar and duct cells and has a major physiologic role in secreting enzymes that are 
essential for the digestive process (Figure 1). Acinar cells, which account for around 80% of 
the pancreatic exocrine cells, have a pyramidal shape that lines up in a single layer and are 
arranged concentrically around a lumen, giving rise to a pancreatic acinus. These cells 
synthesize and secrete digestive enzymes, such as Trypsinogen or Proelastase, in a catalytic 
inactive form into the duodenum through a complex network of ducts (Lack 2003). When these 
zymogens reach the gut they are activated by proteolytic cleavage (Weiss et al. 2008). 
  
 
Figure 1. Sketch of pancreas anatomy. Pancreas is anatomically divided in four different parts: head, 
neck, body and tail (A). The exocrine pancreas represents the major portion of the organ and consists 
of acinar and duct cells (B). Individual acinus encompassing acinar cells organized in a grape-like cluster 
at the smallest termini of the branching duct system (C). The pancreatic islet is embedded in the exocrine 
tissue (D). [Adapted from DePinho et al., 2002] 
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Pancreatic carcinogenesis 
Morphologic perspective 
Different pathologies can arise in pancreas, from diabetes to several clinically and 
pathologically different neoplasms. These can be broadly classified into cystic or solid 
subtypes. The differential diagnosis of these neoplasms has a major importance in patient 
management and prognosis since some of them are known to be precursor lesions of PC. 
The most common solid tumors that arise in the pancreas, accounting for more than 85% 
of all neoplasms, are adenocarcinomas. Histologically they resemble the pancreatic duct 
architecture, reason why they are named pancreatic ductal adenocarcinomas (PDAC) and, 
since they represent the majority of the invasive tumors in pancreas, they are simply called 
pancreatic cancer. Despite all the improvements on the biology and molecular knowledge 
about this pathology, PC remains practically an incurable disease with life expectation 
measured in months. Late diagnosis, namely in stage IIIB or IV which occurs in the majority of 
the patients (nearly 80-85%), contributes to a large extent for the dismal prognosis of this 
disease (Stathis and Moore 2010, Wolfgang et al. 2013). No early detection methodologies 
are available and surgery remains the unique curative treatment. However, surgical resection 
is only an option in pre-cancerous or early-stage (I-II) PC which constitutes only 15-20% of the 
patients and for those the 5-year survival rate is nevertheless 20% (Ahrendt and Pitt 2002). 
Late diagnosis is mostly due to the nonspecific symptoms that only appear when tumors 
metastasize to other organs. These symptoms may vary depending on the localization of the 
primary tumor, in the head, body or tail of the organ, but normally include chronic abdominal 
discomfort, back pain, weight loss, jaundice, occasional glucose intolerance and biliary 
obstruction (Koorstra et al. 2008). 
It is believed that PC is a long-term developing disease being estimated that 10-30 years 
are required since the initiating mutation arises until manifestation of the disease with most of 
the somatic mutations being acquired before the development of the metastatic disease 
(Yachida et al. 2010). Analogous to other carcinomas, it is believed that PC results from a 
stepwise progression process from normal epithelium to invasive carcinoma, which was 
schematized, in a model proposed by Hruban and colleagues (Brat et al. 1998, Hruban et al. 
2000, Koorstra et al. 2008). The most frequent precursor lesion, in around 85% of the cases, 
is the pancreatic intraepithelial neoplasms (PanINs). This lesion is a microscopic (<5 mm 
diameter) mucinous-papillary lesion that arises from the smaller epithelial ducts and is typically 
observed in the surrounding area of the tumor (Andea et al. 2003). PanINs are histologically 
divided into four different categories based on the dysplasia degree in PanIN-1A or PanIN-1B, 
and PanIN-2 or PanIN-3 lesions (Figure 2) (Hruban et al. 2000, Hruban et al. 2001, Hruban et 
al. 2004). These lesions have been extensively studied and with the advances in the 
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technology the genetic alterations associated with them are now relatively well known, which 
was crucial to establish PanIN as precursor lesions of PC since they share genetic alterations. 
 
 
Figure 2. Progression model of pancreatic adenocarcinoma. Transformation of a normal duct 
epithelium into adenocarcinoma through a series of histologic and genetic alterations. The thickness of 
the line corresponds to the frequency of a lesion. [Adapted from DePinho et al., 2002; Maitra et al., 2003] 
 
Some pancreatic lesions are benign and do not progress to an invasive carcinoma, 
however others such as intraductal papillary mucinous neoplasm (IPMN), can represent 
precursor lesions of invasive ductal adenocarcinoma and therefore can constitute a window of 
opportunity to an early diagnosis and more effective treatment. IPMNs account for around 25-
30% of all pancreatic cystic lesions and are defined as mucin-producing epithelial neoplasms 
that can involve the major pancreatic duct, the branch ducts or both (Nagai et al. 2008). They 
are noninvasive and classified according to the dysplasia grade into low-grade dysplasia 
(adenoma), intermediate-grade dysplasia (borderline) and high-grade dysplasia (carcinoma in 
situ). Approximately one-third of the patients diagnosed with IPMNs already present with an 
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associated invasive carcinoma at the time of diagnosis (Niedergethmann et al. 2008, Matthaei 
et al. 2011, Distler et al. 2013, Zamboni et al. 2013). Histologically, based on cytoarchitectural 
features and immunophenotype, IPMNs can be sub-divided in intestinal, oncocytic, 
pancreatobiliary and gastric subtype (Furukawa et al. 2005). This histopathologic subdivision, 
together with the lymph node ratio and the presence or not of invasive carcinoma, plays an 
important role in the prognosis of these lesions and, after surgical resection of noninvasive 
IPMN, 5-year survival rates are reported to be at 77-100% (Niedergethmann et al. 2008, 
Furukawa et al. 2011, Kim et al. 2011). Another cystic lesion known as a precursor lesion of 
PC is the mucinous cystic neoplasm (MCN) (Zamboni et al. 2013). In contrast with IPMNs, 
MCNs don’t establish contact with the larger pancreatic ducts and are more prevalent in 
women (Distler et al. 2014). Like IPMNs, they are subdivided based on the grade of dysplasia 
and about one-third of them become invasive (Baker et al. 2012). Nevertheless, the five-year 
survival of noninvasive MCN is almost 100% and even in patients that need to undergo 
resection due to invasive MCN the five-year survival is around 60% (Baker et al. 2012). 
Pancreatic neuroendocrine tumors (PanNETs) are the second most common solid type of 
pancreatic neoplasm and can involve any part of the pancreas. PanNETs are fully malignant 
tumors with a less invasive phenotype than PDACs and with a ten-year survival rate of 45% 
(Reid et al. 2014). 
The diagnosis of pancreatic cystic neoplasms (PCNs) is increasing due to advances in 
cross-scan imaging technics, such as computed tomography (CT) and magnetic resonance 
imaging (MRI). These lesions are not uncommon, being present in around 1.9% of the patients 
that undergo imaging diagnosis for suspicion of pancreatic disease (Zhang et al. 2002). 
Furthermore, they are detected in 2.6% of the asymptomatic patients (Canto et al. 2012). 
Solid-pseudopapillary neoplasms (SPNs), also known as solid and papillary tumors, 
papillary cystic tumors, solid cystic tumors, Frantz tumors and Hamoudi tumors are rare and 
almost only present in young women (Martin et al. 2002, Ng et al. 2003). Although these lesions 
are usually related with a good prognosis, they are malignant neoplasms with an invasive 
phenotype and metastasize in 10% to 15% of the patients (Tang et al. 2005, Reddy et al. 
2009). Finally, serous cystic neoplasms (SCNs) are almost always benign lesions not removed 
by surgery unless they are large or cause symptoms and can be clinically followed (Wargo et 
al. 2009). 
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Molecular perspective  
Sporadic PC results from the accumulation of acquired mutations. The earlier and most 
frequent point mutation in pancreatic tumorigenesis occurs in KRAS oncogene (Hruban et al. 
1993, Moskaluk et al. 1997). Activating point mutations in this gene are present in more than 
90% of the tumors making PC the neoplasia most frequently associated with mutations in the 
KRAS oncogene (Hruban et al. 1993). The majority of KRAS mutations occur in codon 12 of 
the gene being the G12D the most prevalent one (Jimeno and Hidalgo 2006, Goggins 2007, 
Singh and Maitra 2007, Koorstra et al. 2008). They lead to constitutively activation of the Ras 
protein, which is involved in cell-cycle control, triggering uncontrolled stimulatory signal to 
downstream signaling pathways such as RAF mitogen-activated protein kinase, 
phosphatidylinositol 3´-kinase (PI3K), and RalGDS pathways (Shields et al. 2000, Jimeno and 
Hidalgo 2006, Koorstra et al. 2008).  KRAS mutations are found occasionally in histologically 
normal pancreas and in 36% of PanIN-1A, 44% of PanIN-1B, and 87% of PanIN-2/PanIN-3 
lesions (Sturm et al. 1998, Luttges et al. 1999, Tascilar et al. 1999, Hingorani and Tuveson 
2003, Hruban et al. 2008). Although specific KRAS downstream pathways in pancreatic 
carcinogenesis are not yet fully understood, there are evidences of epidermal growth factor 
(EGF) family signaling involvement (Korc et al. 1992, Watanabe et al. 1996, Overholser et al. 
2000). Interestingly, EGF family receptors, such as epidermal growth factor receptors ErbB1 
and ErbB2, are overexpressed in pancreatic carcinogenesis since low-grade PanIN lesions 
which points to a role of these proteins in the earliest stages of pancreatic neoplasias together 
with KRAS activation (Day et al. 1996). The screening of KRAS mutations is easy, however, 
considering that not all of the KRAS positive neoplasias will progress to PC the diagnostic 
value of these mutations alone is not very relevant. As a therapeutic target in PC, KRAS has 
been disappointing until now (Karp and Lancet 2007). 
Mutations in tumor suppressor genes also contribute to pancreatic carcinogenesis being 
the most relevant mutations in the CDKN2A, TP53 and DPC4/SMAD4 genes. Inactivation of 
p16/CDKN2A tumor-suppressor gene is present in 90% of all PC. It is detected in 30% of 
PanIN-1, 55% of PanIN-2 and 70% of the PanIN3 lesions, indicating that it is a relatively early 
event in pancreatic carcinogenesis (Wilentz et al. 1998). Loss of p16/CDKN2A function can 
occur by homozygous deletion, intragenic mutation and loss of the second allele or by promoter 
hypermethylation (Caldas et al. 1994, Schutte et al. 1997). p16 protein is important in cell cycle 
G1/S checkpoint. This protein binds to CDK4 and CDK6 proteins leading to Rb-1 
phosphorylation inhibition and consequent cell cycle arrest (Sherr 2000). Loss of p16 function 
leads to an aberrant Rb-1 phosphorylation that results in inappropriate progression through 
the cell cycle, decreasing apoptosis and increasing cell proliferation (Sellers et al. 1995). 
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Another frequent genetic alteration in pancreatic carcinogenesis is inactivation of the TP53 
tumor suppressor gene. TP53 gene is the most frequently inactivated tumor-suppressor gene 
among all human solid tumors. This gene is inactivated in around 70% of all PC most frequently 
through an intragenic mutation and loss of second allele (Goggins 2007, Koorstra et al. 2008). 
The protein encoded by this gene is involved in a number of important biological processes, 
namely in the regulation of apoptosis as a response to cytotoxic stress and in DNA repair 
during cell cycle arrest (Kern 1994). As a result of inactivation of this protein, cell proliferation 
and apoptosis are deregulated contributing to tumor progression. 
DPC4/SMAD4 tumor suppressor gene is also frequently inactivated during pancreatic 
carcinogenesis. Like TP53, inactivation of this gene occurs relatively late in pancreatic 
carcinogenesis being present in 30-40% of all PanIN-3 lesions and invasive carcinomas 
(Wilentz et al. 2000).  SMAD4/DPC4 encoded protein modulates the transforming growth 
factor-β (TGF-β) signaling pathway (Massague et al. 2000). In a normal context, TGF-β 
activation causes SMAD2 and SMAD3 protein phosphorylation and heterodimerizes with the 
SMAD4 protein. The heterodimer translocates to the nucleus where SMAD4 transactivates the 
transcription of specific target genes involved in cell proliferation, angiogenesis, metastasis 
and immune suppression (Blobe et al. 2000). This inactivation is a predictor of worse prognosis 
and has been shown to contribute for cell transformation in a KRAS mutated context 
(Heinmoller et al. 2000, Kojima et al. 2007). 
Mutations in genes involved in DNA repair, such as BRCA2, are also known to contribute 
to pancreatic carcinogenesis in the context of a germline mutation. Germline BRCA2 mutations 
are present in less than 10% invasive PC and this gene is important in repairing DNA-
interstrand cross-links through homologous recombination (Goggins et al. 1996). As some 
chemotherapeutic agents, such as cis-platinum and mitomycin, introduce these DNA-
interstrand crosslinks, tumors harboring mutations in BRCA2 are expected to be more 
susceptible to treatment with these agents (van der Heijden et al. 2005). Somatic mutations 
(inactivation of the second allele) in BRCA2 are found in PanIN-3 lesions but are absent in low-
grade lesions, suggesting that this is a late event in PC carcinogenesis (Goggins et al. 2000). 
Cytogenetic studies have shown that telomere dynamics contribute to genomic instability. 
Despite telomerase reactivation being necessary for immortalization of cancer cells, the 
telomere shortening that leads to the formation of chromosomal rearrangements by an 
abnormal fusion of the chromosome ends is an early event in this process (Artandi et al. 2000, 
Maser and DePinho 2002). In this context, the cell death that normally occurs in response to 
the presence of critically short telomeres, is overcomed by the inactivation of the DNA-repair 
machineries allowing oncogenic chromosomal alterations (Chin et al. 1999, Gisselsson et al. 
2001). An analysis of a large panel of PC cell lines reveals that short telomeres and genomic 
instability are associated in this model (Gisselsson et al. 2000, Gisselsson et al. 2001). As 
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these features were observed both in low and high grade pancreatic tumors, telomere 
shortening is considered to be an early event in pancreatic carcinogenesis. Moreover, it was 
observed that telomerase activation is a late event (Kobitsu et al. 1997, Suehara et al. 1997, 
Gisselsson et al. 2001). More recently, it has been shown that epigenetic abnormalities and 
changes in mRNA expression pattern have a role in pancreatic carcinogenesis (Sato et al. 
2003, Sato et al. 2006, Volinia et al. 2006, Szafranska et al. 2007). 
While it is important to pursue a better understanding of the genetic signature of the 
precursor lesions to improve early diagnosis and treatment, it is crucial to more accurately 
predict which of those lesions will effectively progress to PC in order to identify which patients 
are indeed at risk of developing the disease and to avoid overtreatment. 
 
Cancer Stem Cells 
The cell of origin of human pancreatic cancer remains an unsolved question. Considering 
the ductal morphology of PC, ductal pancreatic cells have been described as the origin of these 
tumors. However, despite the morphological features and the expression of ductal lineage 
genes, the evidences supporting duct cells as the cell of origin remain weak and evidences of 
acinar cells as the cells of origin have been emerging (De La et al. 2008, Habbe et al. 2008, 
Maitra and Leach 2012). These studies, using lineage-specific transgenic expression of mutant 
KRAS, emphasize the importance of acinar to ductal metaplasia in pancreatic carcinogenesis. 
Despite the specific cell origin of PC not being fully elucidated it is now accepted that these 
cells display stemness features and is now debated if they derive from mature cells that 
reacquire stem cell properties during carcinogenesis or from mutated stem cells. These cells 
are called cancer stem cells (CSCs) or tumor-initiating cells and represent a small 
subpopulation of the tumor cells with self-renewal capacity and the ability to give rise to the 
heterogenic cellular subpopulations that are identified in tumors. This subpopulation of cells is 
believed to have the exclusive ability to drive tumor formation, growth, relapse and also 
chemoresistance and has been identified in an ever-increasing number of human tumors (Al-
Hajj and Clarke 2004, Dalerba et al. 2007, Hermann et al. 2007, Li et al. 2009). Therefore 
CSCs have been described as potentially elective targets for therapeutic strategies (Mimeault 
et al. 2007). Several markers have been used to identify and isolate these CSCs from different 
tumor types including colon, prostate, breast and pancreas (Al-Hajj et al. 2003, Collins et al. 
2005, Dalerba et al. 2007, Hermann et al. 2007, Rasheed et al. 2010). In PC, the first study 
was based on the expression of CD44+ CD24+ ESA+ cell surface markers and showed an 
increase in the tumorigenic and self-renewal capacity of this subpopulation of cells, isolated 
from low-passage xenografts, when compared to the remaining tumor cells (Li et al. 2009). 
Pancreatic CSCs were also identified and isolated based on the glycoprotein prominin-1 
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(CD133) surface marker from pancreatic tumor samples. This subpopulation of cells revealed 
an exclusive tumorigenic potential, high resistance to standard chemotherapy and a close 
relationship with the metastatic phenotype (Hermann et al. 2007, Moriyama et al. 2010). The 
pentaspan membrane CD133 was initially described as a cell surface antigen specific for 
hematopoietic stem cells (Yin et al. 1997). Although its biological function remains unclear its 
use in the identification and isolation of CSCs from malignant tumors is now well established 
(Singh et al. 2003, Todaro et al. 2010). 
A better understanding of the mechanisms behind CSC biology could potentiate the 
development of alternative therapies targeting this subset of cells in the expectation to 
overcome chemoresistance and tumor relapse. 
 
            Mucins 
Mucins overview 
Mucins (MUC) are large and heavily O-glycosylated proteins generally expressed in the 
apical surface of epithelial cells being the major compound of the mucus. They are present in 
relatively harsh environments like the digestive and respiratory tract and in the secretory 
epithelia of different organs such as the kidney, liver and pancreas (Forstner 1978). Mucin 
canonical functions are to provide protection from pathogens, dehydration, changes in pH and 
degradative enzymes. All mucins contain a proline, serine and threonine (PTS)-rich tandem 
repeat domain that is heavily O-glycosylated in serine and threonine residues and contributes 
to 50%-80% of the protein total molecular weight (Baldus et al. 2004). The specific sequence 
and the number of tandem repeats are variable among different mucins and individuals, due 
to genetic polymorphisms. N-glycosylation is also often present, although to a much lesser 
degree. The human MUC gene family encodes for up to 21 known proteins that can be divided 
in two main groups: secreted mucins and membrane-associated mucins. Secreted mucins are 
subdivided in two classes: gel-forming mucins (MUC2, MUC5AC, MUC5B, MUC6 and MUC19) 
and non-gel-forming mucins (MUC7) (Bobek et al. 1993, Gum et al. 1994, Desseyn et al. 1997, 
Toribara et al. 1997, Escande et al. 2001). Gel-forming mucins are typically expressed in 
specialized glands or goblet cells and their main function is to create the three-dimensional 
network of the mucus, contributing for their viscoelastic properties, through oligomerization 
domains in order to protect the epithelium against different injuries (Thornton and Sheehan 
2004). On the other hand, non-gel-forming mucins are smaller and unable to oligomerize and 
are mostly secreted by salivary and lachrymal glands (Bobek et al. 1993, Gipson 2004). 
Membrane-associated mucins (MUC1, MUC3A, MUC3B, MUC4, MUC11, MUC12, 
MUC13, MUC15, MUC16, MUC17, MUC20 and MUC21), in addition to their function in 
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protection of the epithelia from adverse conditions, also play important biological roles in cell-
cell and cell-extracellular matrix interaction and signal transduction (Carraway et al. 2003, 
Jonckheere and Van Seuningen 2008). They are anchored at the cell membrane through a 
single hydrophobic transmembrane (TM) domain and, with the exception of MUC4, all of them 
contain a SEA (Sea urchin sperm protein, Enterokinase and Argin) domain in the extracellular 
region (Jonckheere and Van Seuningen 2008). 
 
Mucins in pancreatic carcinogenesis 
The expression profile of mucins as well as the glycosylation pattern are tissue and cell 
type specific and can be modified with cellular differentiation state or under pathologic 
conditions such as tumorigenesis. In the pancreas, MUC1 and MUC6 are the predominantly 
expressed mucins (Balague et al. 1994, Reid et al. 1997). MUC1 is normally present at apical 
membranes of centroacinar cells as well as in the intralobular and interlobular ducts while 
MUC6 expression is mostly restricted to the pancreatic ducts. MUC5B is expressed in both 
acinar and ductal cells (Balague et al. 1994, Balague et al. 1995, Andrianifahanana et al. 2001). 
Secreted MUC2 and MUC5AC mucins and membrane-associated MUC4 mucin are absent or 
weakly expressed (Balague et al. 1994). 
It is well known that mucin expression and the associated glycosylation pattern is altered 
in PC and premalignant lesions. In PanIN lesions, the most relevant precursor lesions of PC, 
the most altered mucins are MUC1 and MUC4. MUC1 expression increases with the 
progression of the PanIN lesion while MUC4 is neo-expressed early in PanIN lesions and its 
expression gradually increases until adenocarcinoma formation (Adsay et al. 2002, Swartz et 
al. 2002, Park et al. 2003). MUC5AC, like MUC4, is not normally expressed in normal pancreas 
being de novo expressed in 70% of early stage PanIN1A lesions and in 85% of PC (Kim et al. 
2002). PanIN lesions also show de novo expression of other mucins such as MUC13, MUC15 
and MUC17, which increases with disease progression to PC (Moniaux et al. 2006, Takikita et 
al. 2009, Haridas et al. 2011, Chauhan et al. 2012). Throughout the progression model, MUC2 
expression remains unchanged (Adsay et al. 2002). 
In IPMN lesions, characterization of mucin expression is used for histopathological 
diagnosis since intestinal, oncocytic, pancreatobiliary and gastric subtypes show a different 
expression pattern of these proteins (Yonezawa et al. 1999, Luttges et al. 2001, Furukawa et 
al. 2005, Kitazono et al. 2013). Intestinal-type IPMN lesions typically express MUC2 and 
MUC5AC and, more recently, a study demonstrated MUC4 expression in these lesions 
(Kitazono et al. 2013). On the other hand, pancreatobiliary-type lesions, normally associated 
with an invasive component, show MUC1 and MUC5AC expression. Oncocytic-type IPMN 
lesions show diffuse expression of MUC5AC and MUC6 whereas MUC1 and MUC2 show focal 
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positivity. Finally, common low-grade gastric-type lesions express MUC5AC and less 
frequently MUC6. In IPMNs, MUC1 expression is correlated with a bad prognosis while 
MUC5AC expression is associated with slow-growing adenomas with good prognosis. Since 
MCN lesions are rare, the available studies about mucin expression are scarce and a 
consensus has not been achieved. Luttges et al. showed that MUC5AC expression is present 
in low-grade lesions, as well as MUC2, while MUC1 is expressed in invasive MCN (Luttges et 
al. 2002). In contrast, Terada et al. reported the expression of MUC1 (7/8 cases), MUC3 (2/8 
cases) and MUC5AC/MUC6 (3/8 cases) and the absence of MUC2 expression (Terada et al. 
1996). 
Aberrant glycosylation is a common feature among essentially all types of cancers, being 
more frequent than changes in the expression profile. In mucins, several tumor-associated 
antigens (TAAs) are found and, despite the number of biomarkers under investigation, the only 
biomarker in PC used in the clinical practice is based on a glycan epitope that is found in 
mucins. The sialylated Lewis blood group antigen or carbohydrate antigen 19-9 (CA19-9) 
recognizes the sialyl Lewis A oligosaccharide structure and increased levels of this antigen in 
the serum are correlated with tumor burden increase and poor prognosis (Magnani et al. 1983, 
Rhodes 1999). This biomarker is elevated in approximately 75% of PC patients with a 
sensitivity of 70% and a specificity of 87% (Steinberg 1990, Fong and Winter 2012). The major 
drawback of this biomarker is that it can be detected among patients with benign 
pancreaticobiliary disorders and is often normal in patients that harbor preinvasive lesions such 
as IPMNs and high-grade PanIN (Canto et al. 2006). Furthermore, 5-15% of the population 
does not even express Lewis antigens. For these reasons, CA19-9 is not recognized as a good 
early diagnostic tool and is mostly used in the clinical practice to monitor disease burden and 
response to therapy. 
It is expected that recent advances in technology together with a better understanding of 
cell biology might lead to the identification of novel biomarkers relevant for PC early diagnosis 
and screening together with new targets for the development of new therapies to overcome 
the dismal prognosis of this disease (Melo et al. 2015, Sausen et al. 2015). 
 
MUC1 
MUC1 in cancer 
As previously described, both the glycosylation and the expression of mucins are 
deregulated during pancreatic carcinogenesis. One of the most deregulated mucins is MUC1, 
reason why it will be described in more detail here. 
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Mucin 1 (MUC1; also known as episialin, PEM, H23Ag, EMA, MCA and CA15-3) was the 
first mucin to be cloned and until now it remains the best studied protein of this family. MUC1 
is normally present at the apical surface of polarized epithelial cells and was also described as 
being present in hematopoietic and stem/progenitor cells (Agrawal et al. 1998, Brugger et al. 
1999, Dent et al. 1999, Hikita et al. 2008). The MUC1 gene is located in the long arm of 
chromosome 1 in position 21 (locus 1q21), and comprises seven exons ranging about 4.4kb. 
The mature MUC1 protein encompasses two subunits, the extracellular N-terminal subunit that 
comprises the signal sequence and the variable number tandem repeat (VNTR) domain, and 
the C-terminal subunit that comprises an extracellular stem region, a short transmembrane 
domain and the cytoplasmic domain (MUC1-CD) (Figure 3) (Gendler et al. 1990, Lan et al. 
1990). The VNTR region consists of a closely identical sequence of 20 amino acids (aa) 
repeated 25 to 125 times. This glycoprotein is synthesized as a single polypeptide chain being 
autoproteolytically cleaved in the endoplasmic reticulum soon after synthesis and is present, 
in normal conditions, on the cell surface as a heterodimer (Parry et al. 2001, Singh and 
Hollingsworth 2006). Cleavage of the MUC1 precursor polypeptide occurs between glycine 
and serine residues of the GSVVV motif within the SEA module of the extracellular domain 
(Parry et al. 2001, Wreschner et al. 2002, Lillehoj et al. 2003). In the membrane, the two 
subunits (alpha and beta subunit) bind together through a strong non-covalent interaction 
(Ligtenberg et al. 1992). MUC1 is heavily O-glycosylated mostly in the VNTR region and 
despite N-glycosylation also being present, it is much less frequent, being the glycosylation 
profile of MUC1 dependent on the tissue and on the profile of glycosyltransferases expressed 
(Brockhausen et al. 1995, Remmers et al. 2013). MUC1, similar to other membrane-associated 
mucins, besides playing a central role in maintaining homeostasis and promoting cell survival 
in response to harsh environments, is also involved in cell signaling and transduction events 
mostly through MUC1-CD phosphorylation. 
MUC1-CD, a highly conserved 72 aa sequence, contains several Tyr residues that 
represent potential docking sites for proteins with Src homology 2 (SH2) domains, such as 
protein kinase C (PKCδ), glycogen synthase kinase 3β (GSK-3β) and ErbB receptors like 
ErbB1/epidermal growth factor receptor (EGFR) (Vos et al. 1991, Li et al. 2001). Changes in 
the phosphorylation status of MUC1-CD can modulate its affinity for mediators of signal 
transduction, including β-catenin and p53 proteins (Figure 3) (Ren et al. 2002, Wei et al. 2007). 
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MUC1 is overexpressed in more than 80% of the pancreatic tumors and differs from the 
MUC1 expressed in normal cells with respect to the biochemical features, cellular distribution 
and function, reason why the oncogenic role of MUC1 in cancer progression will now be 
reviewed. In tumors, MUC1 overexpression can be due to several mechanisms, including 
increased MUC1 transcription, amplification of MUC1 genomic locus or loss of post-
transcriptional regulation (Merlo et al. 1989, Lagow and Carson 2002, Ahmad et al. 2009, 
Rajabi et al. 2010). In tumor cells, MUC1 has fewer, shorter and less branched glycans which 
is in contrast with normal cells that normally show more elongated and highly branched glycans 
(Lloyd et al. 1996). This, together with the different expression levels and cellular localization 
led to the establishment of MUC1 as a TAA. The hypoglycosylation of MUC1 in cancer cells 
impacts the stability and the subcellular localization of the protein, increasing the intracellular 
uptake by clathrin-mediated endocytosis. As a consequence, and since MUC1 degradation is 
not increased, there is an intracellular accumulation of this protein (Altschuler et al. 2000). 
MUC1 glycosylation has also been associated with inflammatory response since its dense 
glycan part entraps proinflammatory factors such as transforming growth factorα (TGF-α), 
interleukin 1 (IL-1) and interleukin 4 (IL-4), among others, that are released after MUC1-N 
shedding, inducing an inflammatory response (Cebo et al. 2001). Due to the loss of polarity in 
tumor cells, MUC1 is no longer restricted to the apical surface being instead spread over the 
entire cell surface (Figure 4). This loss of polarity disturbs the cell-cell and/or cell-matrix 
interactions, favoring the release of tumor cells into the blood circulation and moreover, 
enabling the interaction between MUC1 and other membrane proteins normally restricted to 
the basolateral domain of the cells, such as growth factor receptors (Schroeder et al. 2001). 
Interactions with these proteins could contribute to the growth and survival of tumor cells 
through activation of signaling pathways or by blocking the access of other molecules to these 
receptors (Hollingsworth and Swanson 2004). 
 
Figure 4. MUC1 in normal vs MUC1 in cancer cells. MUC1 is confined to the apical surface of normal 
epithelial cells. However, in tumor cells this polarity is lost and no longer restricted to the apical surface 
Chapter 1 | General Introduction   
18 
 
being instead spread over the entire cell surface which potentiates the interaction between MUC1 and 
RTKs. These interactions could contribute to activation of signaling pathways or to block the access of 
other molecules to these receptors. Hypoglycosylation of MUC1 is also represented. 
 
Although the establishment of MUC1 as an oncogene is not consensual, its involvement 
in proliferation, angiogenesis, invasion and metastization is now well documented. Studies in 
transgenic mice and different cell lines have related MUC1 with carcinogenesis in different 
ways being hypothesized that, globally, MUC1 participates in the control of the local 
microenvironment allowing the tumor to adapt, survive and proliferate in invasive and 
metastatic microenvironments. The discovery that overexpression of MUC1-CD alone is 
sufficient to induce anchorage-independent growth and tumorigenicity of carcinoma cells in 
vitro led to a stronger focus of the research in this subunit of MUC1 (Huang et al. 2003). MUC1-
CD signaling at the cell membrane is triggered by phosphorylation of the serine and threonine 
residues. This phosphorylation can occur in response to the activation of several surface 
growth factor receptors, namely, platelet-derived growth factor receptor (PDGFR) and 
members of the Erb family which include EGFR and ErbB2/Her2 (Riese and Stern 1998, 
Schroeder et al. 2001, Singh et al. 2007). Binding of the ligands to the extracellular domain of 
these receptors leads to the formation of a dimer that is followed by cross-phosphorylation of 
MUC1-CD that starts working as a docking site for the activation of different signaling pathways 
important in cellular proliferation, differentiation, migration and survival such as PI3K and 
mitogen-activated protein kinase (MAPK) pathways (Schlessinger 2000). 
MUC1-CD is also a target of several different kinases including PKCδ, GSK-3β and the 
tyrosine kinases c-Src and Lck (Thompson et al. 2006). Phosphorylation events regulate the 
interaction between MUC1-CD and other intracellular binding partners such as the Wnt 
pathway effector or β-catenin (Yamamoto et al. 1997, Li et al. 2001, Kufe 2009). β-catenin 
binds to MUC1-CD through a motif similar to those present in E-cadherin and the adenomatous 
polyposis coli (APC), at the SXXXXXSSL sequence (Yamamoto et al. 1997). This interaction 
is dependent of MUC1-CD phosphorylation by c-src kinase and is inhibited by GSK-3β 
phosphorylation (Li et al. 2001). MUC1-CD/β-catenin complex leads to an accumulation of β-
catenin in the nucleus where it acts as a transcriptional coactivator of genes controlling cellular 
growth, such as cyclin-D1 and c-myc, promoting tumor progression (Smalley and Dale 2001). 
Moreover, MUC1-CD/β-catenin interaction decreases the ability of β-catenin to interact with E-
cadherin at adherens junctions leading to a decrease in cell-cell interaction (Li et al. 1998). β-
catenin in the nucleus also represses E-cadherin expression and induces the transcription of 
epithelial-mesenchymal transition (EMT) inducers such as Snail, Slug, Vimentin and Twist, 
enhancing the invasive potential of tumor cells (Kalluri and Weinberg 2009, Roy et al. 2011). 
MUC1 and β-catenin don’t interact in a normal polarized epithelium since they have different 
   Chapter 1 | General Introduction 
19 
 
subcellular localizations. EMT is also induced by MUC1 through regulation of miRNA involved 
in EMT-gene expression (Mohr et al. 2013, Rajabi et al. 2014). 
Angiogenesis is another hallmark of cancer in which MUC1 plays a role. The growing of a 
tumor mass creates a low oxygen and nutrient microenvironment (hypoxia) that induces tumor 
cells to express proangiogenic factors, promoting growth of new vessels in order to adapt and 
survive in this environment. It has been demonstrated that MUC1 stimulates the expression of 
proangiogenic factors like the connective tissue growth factor (CTGF), platelet-derived growth 
factor subunit B (PDGF-B) and endothelial growth factor-A (VEGF-A), which are responsible 
for the synthesis of new blood vessels within the tumor that provide oxygen and nutrients 
(Kitamoto et al. 2013). In pancreatic cancer, it was also reported that MUC1 overexpression 
induces the synthesis and secretion of vascular endothelial growth factor (VEGF) through the 
AKT signaling pathway (Woo et al. 2012). 
MUC1 overexpression also confers the cell survival advantages by blocking cell death 
mediated by both the intrinsic and extrinsic apoptosis pathways. MUC1-CD is able to bind to 
heat shock proteins 70 or 90 (HSP70 or HSP90). They are translocated as a complex to the 
mitochondria where MUC1-CD blocks the loss of mitochondrial transmembrane potential 
abolishing apoptosis response to oxidative, genotoxic, hypoxic and metabolic stress (Ren et 
al. 2004, Ren et al. 2006, Ren et al. 2006). Direct interaction between p53 and MUC1-CD was 
also reported in response to genotoxic stress, promoting the transcription of p53-target genes 
(Wei et al. 2005). A recent study showed that MUC1 overexpression in PC cells increases 
chemoresistance by upregulating multidrug resistance genes, in particularly, the ABCC1 gene 
that encodes for the multidrug resistance protein 1 (MRP1) (Nath et al. 2013). 
The evidences of MUC1 involvement in tumor progression and the reports of MUC1 
peptides and small molecule inhibitors as effective inhibitors of cancer progression, both in 
vitro and in vivo, led to the development of MUC1-based therapies (Tinder et al. 2008, Bitler 
et al. 2009, Besmer et al. 2011, Raina et al. 2011). However, all of them are relatively recent 
and clinical trials are still ongoing in different models, namely, multiple myeloma, breast, 
prostate, colorectal and pancreatic tumors, in order to understand the potential of these 
targeted therapies. 
 
MUC1 splice variants 
Alternative splicing is a key process in the regulation of gene expression contributing to 
the heterogeneity of the transcriptome and proteome and is estimated to occur in over 95% of 
all multiple-exon human genes. This mechanism generates multiple mRNAs from a single 
gene during pre-mRNA maturation and results in a variety of different proteins, that differ in 
their amino acid sequence. Alternative splicing has been associated with a large number of 
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diseases, including cancer (Wang et al. 2008). MUC1 has alternative isoforms generated by 
different splicing pathways, including exon skipping, full or partial intron retention and 
alternative 5′ and 3′ splice sites (Zhang et al. 2013) The best characterized MUC1 isoform is 
the polymorphic mucin-like type 1 transmembrane protein, MUC1/REP or MUC1/TM, which 
represents the full molecule. MUC1/SEC, a secreted truncated isoform, retains the VNTR 
region and is devoided of the transmembrane and cytoplasmic region, being mostly associated 
with absence of malignancy. This isoform was identified as being secreted by several different 
cells, such as breast and colon cells, benign ovarian tumors, in the sera of breast cancer 
patients and also in human milk (Smorodinsky et al. 1996, Xing et al. 2001, Obermair et al. 
2002, Hey et al. 2003 ). Although more than 70 isoforms have been identified, the full length 
sequence has only been reported for some. 
Recently, 78 different MUC1 isoforms were isolated from human cervical and breast 
cancer cell lines and from human activated T cells, being MUC1/A, MUC1/B, MUC1/C, 
MUC1/D, MUC1/X, MUC1/Y and MUC1/ZD the most abundant ones (Zhang et al. 2013). This 
study identified exon 2, which contains the VNTR region, as the most skipped exon among all 
different isoforms using the same 5’ splice site and variable 3’ splice sites. The authors point 
several different reasons for this to occur, namely, the large size of this exon which can be as 
high as 6,200bp; the presence of core splicing signals in the VNTR sequence, such as the 5’ 
splice site, the 3’ splice site and the branch point site; the presence of cis-regulatory elements 
at the junction of the repeats that have been described as intron splice enhancers, or the 
existence of Nova splicing factor binding sites (YCAY, with Y being any pyrimidine) in each 
repeat, which can result in a blockage of exon inclusion when bound by Nova. On the other 
hand, the MUC1-CD region remains unchanged in almost all MUC1 short isoforms, allowing it 
to keep the important signaling function (Zhang et al. 2013). 
MUC1/A, MUC1/B, MUC1/C and MUC1/D encode a “full-length” MUC1 having a fixed 
splice donor site near the 5´ end of intron 1 and variable splice acceptor sites near the 3´ and 
5´ end of intron 1 and exon 2, respectively. MUC1/A retains 27bp of intron 1 without causing a 
reading frameshift while MUC1/B has intron 1 completely excised. MUC1/C and MUC1/D show 
excision of portions of exon 2, 9bp and 35bp, respectively, keeping the reading frame 
(Oosterkamp et al. 1997, Obermair et al. 2001). MUC1/A and MUC1/B are differentially 
expressed in prostate, cervical, ovarian and breast cancer (Obermair et al. 2002, Schmid et al. 
2003, Strawbridge et al. 2008).  
MUC1/Y, MUC1/X and MUC1/ZD splice variants arise from a fixed splice donor at the 
5´end of exon 2 and different splice acceptor sites around the 3′ end of exon 2 resulting in 
MUC1 isoforms that lack the VNTR region but retain the transmembrane and cytoplasmic 
domain. MUC1/Y, an uncleaved splice variant, doesn’t exhibit mucin-like features altough it is 
expressed by diverse human secretory epithelial tumors, being undetectable in the adjacent 
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normal tissue and was shown to be involved in tumor initiation and progression in vivo, in 
breast cancer (Zrihan-Licht et al. 1994, Baruch et al. 1999, Hartman et al. 1999, Levitin et al. 
2005). It was described that MUC1/Y undergoes tyrosine/serine phosphorylation being 
potentially able to interact with proteins containing a SH2 domain, such as Grb2, triggering a 
cell signaling cascade and working in a similar way to cytokine receptors. (Zrihan-Licht et al. 
1994, Baruch et al. 1999). MUC1/SEC is capable of binding to MUC1/Y in a region homologous 
to the ligand binding sites of cytokine receptors, inducing its phosphorylation and stimulating 
cell signaling pathways (Baruch et al. 1999). MUC1/Y was also shown to be overexpressed in 
ovarian and prostate cancer and associated with breast cancer (Baruch et al. 1997, Hanisch 
and Muller 2000, Schut et al. 2003) 
MUC1/X and MUC1/ZD were also associated with malignant ovarian tumors (Obermair et 
al. 2002). MUC1/X, like MUC1/Y, misses the VNTR region but has a different acceptor site 18 
aa upstream to MUC1/Y. It is highly expressed in cervical and ovarian cancer cells and contrary 
to MUC1/Y, this isoform undergoes proteolytic cleavage (Baruch et al. 1997, Levitin et al. 2005, 
Levitin et al. 2005, Kumari and Sudandiradoss 2013). MUC1/ZD also lacks the VNTR region 
and contains a unique C-terminal sequence of 43 aa resulting from a shift in the reading frame 
(Levitin et al. 2005). 
More recently, a truncated genomic fragment of human MUC1 was shown to induce 
epithelial to mesenchymal transition in mammary mouse cells (Horn et al. 2009). In addition, a 
MUC1 transmembrane cleaved form (MUC1*) was reported to have an important role in 
chemoresistance to standard chemotherapy agents (Fessler et al. 2009) as well as to be an 
accurate marker of pluripotency in human embryonic stem cells (Hikita et al. 2008). This 
isoform contains only 45 aa of the MUC1 extracellular domain, lacking the VNTR region. 
Currently, there is a lack of clear understanding about the expression and the biological 
function of all these splice variants mostly due to the absence of specific antibodies. 
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Figure 5. Schematic representation of the MUC1 gene and the different isoforms. (A) The MUC1 
gene comprises seven exons (E1 to E7 colored boxes) and six introns (I to VI). Exons encoding the 
corresponding domains are indicated by an arrow. (B) MUC1 pre-mRNA is spliced into four main 
variants of mature MUC1 mRNA – MUC1/A, MUC1/B, MUC1/C, and MUC1/D. (C) MUC1/X (or 
MUC1/Z), MUC1/Y, and MUC1/ZD splice variants, which completely lack the VNTR region as well as 
the truncated MUC1/SEC isoform (adapted from Nath et al., 2014). 
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Pancreatic cancer remains one of the deadliest human malignancies despite the scientific 
and clinical efforts in the field. This panorama is mainly due to an absence of consistent 
symptomatology in the early stages of the disease and the lack of more accurate diagnosis 
techniques and molecular markers that together impair an early diagnose. Surgery remains 
the unique hope of cure and, even when possible, the success of this approach is limited while 
other treatment options do not bring a remarkable survival improve. Therefore, it is urgent to 
better understand the biology and molecular background of this disease to anticipate the 
diagnosis of individuals with pancreatic cancer and to develop new target therapies. 
Since MUC1 cloning in 1990, a lot has been learnt on its role in tumor promotion, 
progression and relapse and its association with pancreatic cancer is now well established. 
Nevertheless, several questions remain to be answered such as the involvement of MUC1 in 
the stem phenotype of the pancreatic CSC subpopulation and the relevance of alternative 
splice variants of this gene in the pancreatic carcinogenesis. 
Taking these questions into account, the general aim of the present work was to determine 
the involvement of MUC1 in the CSC phenotype and to investigate the biological function of 
MUC1 splice variants in pancreatic carcinogenesis. 
 
 
Specific objectives 
1. Evaluate the involvement of MUC1 in pancreatic CSCs phenotype; 
In the first part of the work we evaluated the involvement of MUC1 and its signaling partners 
in the phenotype of pancreatic tumor-initiating cells expressing the CD133 surface marker. We 
used magnetic cell sorting (MACs) to select a population enriched in CD133 expressing cells 
from a pancreatic cell line. The stemness potential of the generated cells was validated through 
a tumorigenic assay. 
The expression profile of MUC1 and putative signaling partners was assessed in this 
subpopulation of cells to evaluate the involvement of MUC1-mediated oncogenic signaling 
cascades in pancreatic tumor-initiating cells.     
  
2. Evaluate the involvement of MUC1 splice variants in the phenotype of pancreatic 
tumors; 
In the second part of the work we evaluated the impact of MUC1/S2 splice variant in the 
pancreatic tumor phenotype and oncogenic signaling. We overexpressed, in a pancreatic 
tumor cell line, the MUC1/S2 splice variant and characterized its sub-cellular localization. 
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Proliferation, invasion, migration and MUC1-p53 interaction was also evaluated in the 
generated cells. 
 
3. Highlight scientific advancements in MUC1 research with a special emphasis in cell 
differentiation and MUC1 splice variants raising future points of interest in this 
research area.  
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Abstract 
 
Despite the fact that the biological function of cluster of differentiation (CD)133 remains 
unclear, this glycoprotein is currently used in the identification and isolation of tumor-initiating 
cells from certain malignant tumors, including pancreatic cancer. In the present study, the 
involvement of mucin 1 (MUC1) in the signaling pathways of a highly tumorigenic CD133+ 
cellular subpopulation sorted from the pancreatic cancer cell line HPAF‐II was evaluated. The 
expression of MUC1‐cytoplasmic domain (MUC1‐CD) and oncogenic signaling transducers 
(epidermal growth factor receptor, protein kinase C delta, glycogen synthase kinase 3 beta 
and growth factor receptor‐bound protein 2), as well as the association between MUC1 and 
β‐catenin, were characterized in HPAF‐II CD133+ and CD133low cell subpopulations and in 
tumor xenografts generated from these cells. Compared with HPAF CD133low cells, HPAF‐II 
CD133+ cancer cells exhibited increased tumorigenic potential in immunocompromised mice, 
which was associated with overexpression of MUC1 and with the accordingly altered 
expression profile of MUC1‐associated signaling partners. Additionally, MUC1‐CD/β-catenin 
interactions were increased both in the HPAF‐II CD133+ cell subpopulation and derived tumor 
xenografts compared with HPAF CD133low cells. These results suggest that, in comparison 
with HPAF CD133low cells, CD133+ cells exhibit higher expression of MUC1, which contributes 
to their tumorigenic phenotype through increased interaction between MUC1‐CD and β-
catenin, which in turn modulates oncogenic signaling cascades. 
 
Introduction 
The pentaspan membrane glycoprotein prominin-1, also known as cluster of 
differentiation (CD)133, was initially described as a cell surface antigen specific for 
hematopoietic stem cells and progenitor cells (1,2). The biological function of CD133 remains 
unclear. However, it is currently used in the identification and isolation of tumor-initiating cells 
from certain malignant tumors, whereby it correlates with poor prognosis (3–5). Tumor-
initiating cells, also called cancer stem cells (CSCs), are characterized by their self-renewal 
capacity and the ability to generate cell subpopulations during tumor growth (6–8). Although 
CD133 is a reasonable marker of various CSCs, several types of cancer arise from cells with 
different markers (9,10). 
Pancreatic cancer is the fifth most lethal cancer in developed countries, with a 5-year 
survival rate of <6% (11). Early metastasis, late diagnosis and the low effectiveness of the 
currently available therapies contribute to its high mortality rate (12). A previous study on 
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pancreatic cancer identified that cells expressing CD44, CD24 and epithelial-specific antigen 
surface markers were associated with an increase in the tumorigenic and self-renewal capacity 
of tumor cells isolated from primary tumors or low-passage tumor xenografts (8). However, 
these markers do not identify CSCs within all pancreatic tumors, and other studies revealed 
that the use of CD133 to isolate tumor-initiating cells yielded populations of cells with enhanced 
tumorigenic potential, high resistance to standard chemotherapy and a close association with 
metastatic phenotype (7,13). In addition, a recent study confirmed that enforced expression of 
CD133 enhanced the aggressive behavior of pancreatic cancer cells (14). 
MUC1 is a heavily glycosylated transmembrane glycoprotein expressed at low levels in 
the apical surfaces of epithelial cells (15). This glycoprotein possesses oncogenic properties, 
and is overexpressed in >80% of pancreatic tumors, contributing to tumor progression, 
metastasis and mortality in patients with pancreatic cancer (16–20). The MUC1 gene encodes 
a protein comprised of a large extracellular domain with a tandem repeat region, a 
transmembrane domain and a highly conserved cytoplasmic domain (MUC1-CD), which 
participates in several oncogenic signaling pathways (21). MUC1-CD is highly conserved, and 
contains seven tyrosine residues and several serine and threonine residues that represent 
potential docking sites for proteins with Src homology 2 domains and recognition sites for 
receptor tyrosine kinases and other kinases, including protein kinase C delta (PKCδ), glycogen 
synthase kinase 3 beta (GSK3β) and ErbB receptors such as epidermal growth factor receptor 
(EGFR) (22). Furthermore, MUC1-CD contains a serine-rich motif that functions as a β-catenin 
binding site, and the phosphorylation of MUC1-CD modulates this affinity (23). MUC1-CD/β-
catenin interactions enhance the malignant phenotype of tumor cells by regulating the activity 
of the T-cell factor/lymphoid enhancer factor (TCF/LEF) family of transcription factors, thus 
modulating the expression of several genes involved in the tumorigenic phenotype, including 
target genes in the Wnt signaling pathway (24). Recently, a transmembrane cleaved form of 
MUC1 has been reported to exert an important role in chemoresistance to standard 
chemotherapy agents (25), and to potentially serve as an accurate marker of pluripotency in 
human embryonic stem cells (26). The expression of MUC1 in CSCs has been documented 
by a novel antibody against tumor-associated MUC1 that recognizes a sequence in the tandem 
repeat region of MUC1, which is different from the sequences recognized by the majority of 
commercially available antibodies against MUC1 (27). 
Based on the reported associations of MUC1 with CSCs, the present study aimed to 
investigate the potential contribution of MUC1 to the oncogenic signaling pathways of CD133+ 
pancreatic cancer cells. The results revealed that MUC1/β-catenin interactions are associated 
with enhanced tumorigenic properties of CD133+ pancreatic cancer cells. 
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Material and methods  
 
Cell culture 
The human pancreatic cell line HPAF-II was obtained from the American Type Culture 
Collection (Manassas, VA, USA), and was cultured in RPMI 1640 medium Gibco; Thermo 
Fisher Scientific Inc.,Waltham, MA USA containing GlutaMAXTMI (Gibco; Thermo Fisher 
Scientific, Inc.) and 25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (Gibco; Thermo 
Fisher Scientific, Inc.), supplemented with 10% fetal bovine serum (Gibco; Thermo Fisher 
Scientific, Inc.) and 50 mg/ml gentamicin (Invitrogen; Thermo Fisher Scientific, Inc.). Cells were 
grown at 37°C with 5% CO2 in a humidified atmosphere. 
 
CD133 cell-surface expression analysis by flow cytometry 
The expression levels of CD133 in the HPAF-II cell line were assessed by flow cytometry 
with an anti-CD133/2-phycoerythrin (PE) monoclonal antibody (MAb) [#130-080-901; mouse 
immunoglobulin (IgG)1; Miltenyi Biotec GmbH, Bergisch Gladbach, Germany]. A mouse IgG1 
MAb served as a control (#130-092-212; Miltenyi Biotec GmbH). 
To perform flow cytometry analysis, cells were trypsinized when 80% of confluence was 
reached. For each analysis, 5×105 cells were used. Cells were incubated with a mouse IgG1 
MAb solution (1:80) for 10 min at 4°C, and next resuspended in an anti-CD133/2-PE antibody 
solution (1:10) for 10 min at 4°C in the dark. Upon incubation, the cells were washed with 0.1% 
PBS two times, and resuspended in 500 µl magnetic-activated cell sorting (MACS) buffer 
[phosphate-buffered saline (PBS) supplemented with 0.5% bovine serum albumin (BSA) and 
2 mM ethylenediaminetetraacetic acid (EDTA)], prior to be analyzed in a FACSCalibur™ flow 
cytometer (BD Biosciences, Franklin Lakes, NJ, USA). A cell suspension that was only 
incubated with mouse IgG1 MAb was used as a control. Analysis of the results was performed 
using FlowJo version 7.2.5 software (FlowJo, LLC, Ashland, OR, USA). 
 
MACs 
Cell subpopulations (CD133− and CD133+) were isolated using a MACS system and 
microbeads coupled to anti-CD133/1 MAb (Miltenyi Biotec GmbH). 
Magnetic separation was performed using the MidiMACSTM magnetic separation kit 
(Miltenyi Biotec GmbH), according to the manufacturer's protocol with minor alterations. Briefly, 
1×108 cells were washed twice with 0.1% PBS and passed through a pre-separation filter (30 
µm) in order to remove cell clumps. Subsequently, the cell suspension was incubated with 
human IgG FcR Blocking Reagent (1:3 in MACS buffer; Miltenyi Biotec, GmbH) and CD133 
microbeads (1:5; Miltenyi Biotec, GmbH) for 30 min at 4°C. Following the incubation step, cells 
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were washed twice with 0.1% PBS, and the pellet was resuspended in 500 µl MACS buffer 
(PBS supplemented with 0.5% BSA and 2 mM EDTA). The cell suspension was then 
transferred to an LS column (Milteny Biotec GmbH) previously hydrated with 3 ml buffer, and 
placed in a magnetic support. The total effluent was collected as the CD133− fraction, and the 
column was then washed three times with 3 ml buffer. Next, the column was removed from the 
magnet and, with the aid of a plunger, 5 ml MACS buffer were used to flush the microbeads-
labeled cells out of the column. The effluent was collected as the CD133+ fraction. 
The CD133− cell subpopulation was subsequently passed through the LS column, and 
washed three times with 1 ml MACS buffer to further deplete the remaining CD133+ cells. Both 
CD133+ and CD133− fractions were centrifuged (300 × g; Centrifuge 5810R; Eppendorf, 
Hamburg, Germany), and the pellets were resuspended in culture medium and maintained at 
37°C in a humidified atmosphere containing 5% CO2. 
 
In vivo tumorigenic assay 
The present in vivo tumorigenic assay was approved by the Institutional Animal Care 
and Use Committee of the University of Nebraska Medical Center (Omaha, USA; protocol 98-
088-03FC). Three groups of non-obese diabetic/severe combined immunodeficiency 
(NOD/SCID) mice (n=5/group) were subcutaneously injected in the right dorsal flanks with 
3,500 HPAF-II cells [wild-type (wt), CD133low or CD133+]. Mice were bred and maintained 
under pathogen-free conditions, which included: A 12 h light/12 h dark cycle, 6 AM/6 PM; water 
bag accessible at all times; Nestlets (Animal Specialties and Provisions, LLC, Quakertown, 
PA, USA) or NestPaks (WF Fisher and Son, Inc., Somerville, NJ, USA) for enrichment; 18–
23°C with 40–60% humidity; and Standard Chow food, similar to LabDiet 5010 (protein 23%; 
fat content not less than 4.5%). Animals were observed twice a day by trained veterinary staff 
and once a day by laboratory staff from the Eppley Institute for Research in Cancer and Allied 
Disease (Omaha, NE, USA). Mice were euthanized 4 weeks following cell injection, which was 
the time point when it was necessary to euthanize the first mouse due to the initial signs of 
suffering. The maximum tumor size achieved was 263.8 mm3. Animals were sacrificed with 
the aid of CO2. Following 5 min without signs of heartbeat or respiration, the animals were 
subjected to cervical dislocation to ensure mortality. Tumors were collected, fixed in 10% 
formalin (Thermo Fisher Scientific Inc.) and embedded in paraffin (Thermo Fisher Scientific 
Inc.) prior to sectioning (Shandon™ Finesse™ 325 microtome; Thermo Fisher Scientific Inc.). 
Growth of internal tumors was evaluated by direct examination (palpation), or by careful 
observation of animal behavior and estimation of post-procedure pain, discomfort, distress or 
morbidity. Anesthesia, when required, was induced by intraperitoneal administration of 
ketamine hydrochloride (100 mg/ml; injectable-RL 3760; NDC-0409-2051-05; Hospira, Inc., 
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Lake Forest, IL, USA) and xylazine hydrochloride (20 mg/ml; injectable-AnaSed NADA; 139–
236; Lloyd, Inc., Shenandoah, IA, USA). 
 
Immunohistochemistry (IHC) 
Tumor xenografts were paraffin-embedded and sectioned at 4-µm thickness. IHC 
staining to detect CD133 protein expression in tumor xenografts was performed using the Dako 
EnVision System (Dako, Glostrup, Denmark). Antigen retrieval was performed in an IHC-Tek™ 
Epitope Retrieval Steamer Set (IHC World, LLC, Woodstock, MD, USA) for 40 min with 10 mM 
citrate buffer pH 6.0 (Thermo Fisher Scientific Inc.), following deparaffinization in xylene 
(Thermo Fisher Scientific Inc.) and rehydration. The slides were cooled for 20 min at room 
temperature, and endogenous peroxidase was blocked with 3% H2O2 (Merck Millipore, 
Darmstadt, Germany) for 5 min. Primary antibody incubation was performed for 1 h at room 
temperature with a mouse anti-human CD133/1 MAb (1:25; clone AC133; Miltenyi Biotech 
GmbH). Slides were next washed in Tris-buffered saline with Tween 20 (Grisp, Porto, 
Portugal), and incubated with Dako REAL EnVision-horseradish peroxidase (HRP) secondary 
antibody (Dako) for 30 min at room temperature. For signal detection, the slides were 
incubated for 5 min with 3,3′-diaminobenzidine chromogen (Dako). Next, tissues were 
counterstained with hematoxylin (Richard-Allan Scientific™; Thermo Fisher Scientific Inc.) for 
3 min, dehydrated, cleared, mounted with Histomount medium (Richard-Allan Scientific™; 
Thermo Fisher Scientific Inc.) and cover slipped. Hematoxylin and eosin (Richard-Allan 
Scientific™; Thermo Fisher Scientific Inc.) staining was performed upon antigen retrieval 
following a standard protocol (28). 
 
Protein extraction and Western blot analysis  
The expression levels of MUC1-CD and oncogenic signaling proteins were evaluated by 
western blotting. Unsorted HPAF-II cells and sorted CD133low and CD133+ cell subpopulations 
were cultured to 80–90% confluence. Upon washing twice with PBS, lysis buffer [10 mM Tris 
pH 7.4, 150 mM NaCl, 0.1% (v/v) sodium dodecyl sulfate (SDS; Bio-Rad Laboratories, Inc., 
Hercules, CA, USA), 1 mM phenylmethylsulfonyl fluoride and 1% (v/v) Triton X-100] was 
added, and cells were scraped. Cell lysates were incubated on ice for 1 h and centrifuged 
(14,000 × g; Centrifuge 5417R; Eppendorf) for 30 min at 4°C to collect the supernatants. 
Protein content was assessed with a bicinchoninic acid protein assay kit (Bio-Rad 
Laboratories, Inc.), as described in the manufacturer's protocol. 
Protein extracts were analyzed by 10% SDS-polyacrylamide gel electrophoresis 
(Invitrogen; Thermo Fisher Scientific, Inc.), transferred to a polyvinylidene fluoride membrane 
(GE Healthcare Life Sciences, Chalfont, UK) and incubated overnight at 4°C with anti-MUC-1 
Chapter 3 | Evaluation of MUC1 involvement in pancreatic CSCs phenotype   
 
54 
 
Armenian hamster MAb (1:300; catalogue no. Ab-5; Thermo Fisher Scientific, Inc.), anti-EGFR 
mouse MAb (1:200; catalogue no. sc-81449; Santa Cruz Biotechnology, Inc., Dallas, TX, 
USA), anti-PKCδ rabbit MAb (1:200; catalogue no. sc-213; Santa Cruz Biotechnology, Inc.), 
anti-GSK3β mouse MAb (1:200; catalogue no. sc-53931; Santa Cruz Biotechnology), anti-
growth factor receptor-bound protein 2 (GRB2) mouse MAb (1:200; catalogue no. sc-8034; 
Santa Cruz Biotechnology, Inc.), anti-β-catenin MAb (1:1,000; catalogue no., 610153; BD 
Biosciences) and anti-β-actin MAb (1:2,000; catalogue no. sc-69879; Santa Cruz 
Biotechnology, Inc.) in 5% non-fat milk diluted in PBS containing 0.1% Tween 20 (Sigma-
Aldrich, St. Louis, MO, USA). Next, membranes were washed three times with PBS containing 
0.1% Tween 20, and incubated with the corresponding goat anti-Armenian hamster (catalogue 
no. sc-2443), anti-mouse (catalogue no. sc-2005) or anti-rabbit (catalogue no. sc-2004) 
peroxidase conjugated antibody (1:2,000; Santa Cruz Biotechnology, Inc.) in 5% non-fat milk 
diluted in PBS containing 0.1% Tween 20. Proteins were visualized using an enhanced 
chemiluminescence detection kit (Bio-Rad Laboratories, Inc.). 
 
Immunoprecipitation assay  
The interaction between MUC1-CD and β-catenin in the HPAF-II cell line was evaluated 
by immunoprecipitation. Proteins from cell lysates (750 µg) were incubated overnight at 4°C 
with protein G-agarose beads (Sigma-Aldrich) previously linked to anti-MUC1 Ab-5 MAb and 
normal Armenian hamster IgG (eBioscience, Inc., San Diego, CA, USA). Following three 
washes, the immune complexes were dissociated from the beads with reducing NuPAGE® 
buffer (Invitrogen; Thermo Fisher Scientific, Inc.). The immunoprecipitates and cell lysates 
were separated in 12% Tris-glycine gels (Invitrogen; Thermo Fisher Scientific, Inc.), and 
immunoblotted following the aforementioned procedure. 
 
In situ Proximity Ligation Assay (PLA) 
PLA was used to assess the close proximity (and putative interaction) between MUC1-
CD and β-catenin in tumor xenografts. PLAs were performed using Duolink® In Situ Detection 
Reagents Brightfield (Olink Bioscience, Uppsala, Sweden), according to the manufacturer's 
protocol. Antigen retrieval was performed in an IHC-Tek™ Epitope Retrieval Steamer Set for 
40 min with 10 mM citrate buffer pH 6.0, following deparaffinization and rehydration. 
Subsequently, the slides were incubated at 37°C for 30 min with a blocking solution (Olink 
Bioscience) in a humidity chamber. 
For β-catenin staining, the mouse primary antibody was used under the same conditions 
as the ones above described for IHC, and a secondary anti-mouse antibody conjugated with 
Duolink® In Situ PLA® Probe Anti-Mouse MINUS (Olink Bioscience) was added, followed by 
1-h incubation at 37°C in a humidity chamber. 
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For MUC1 staining, anti-MUC1 Ab-5 primary antibody directly conjugated with DuolinkII 
Probemarker Plus (Olink Bioscience) was used. The conjugation of the antibody with the probe 
was performed following the manufacturer's protocol, and hybridization was conducted for 1 h 
at 37°C in a humidity chamber. Following the ligation of the probes for 30 min at 37°C, 
amplification of the signal was performed for 120 min at 37°C; both steps occurred in a humidity 
chamber. To detect the signal, the slides were incubated with HRP-labeled probes and 
chromogen (catalogue no., DUO92012-30RXN; Olink Bioscience). Subsequently, tissues were 
counterstained with hematoxylin, dehydrated, cleared and mounted with Histomount medium. 
 
Results 
Isolation of a CD133+ cell subpopulation from the HPAF-II cell line  
Low-passage/highly tumorigenic samples of the HPAF-II cell line (104 cells produced 
tumors in 100% of animals; data not shown) were evaluated for CD133 expression levels by 
flow cytometry. The results indicated that low-passage HPAF-II cells contained ~4% CD133+ 
cells (Fig. 1A). These cells were isolated using MACS, and both CD133+ and CD133− 
subpopulations were cultured. To evaluate the enrichment obtained with the sorting 
methodology used, CD133 was again measured by flow cytometry in the above two cell 
subpopulations prior to injection into immunodeficient mice (Fig. 1B). The results revealed that 
the CD133+ subpopulation was highly enriched in CD133+ cells. However, the putative CD133− 
subpopulation retained a very low percentage of cells expressing CD133, and was therefore 
called CD133low. Repeated selection did not improve the performance of this procedure (data 
not shown). 
The sorted cells were evaluated for tumorigenicity and tumor phenotype. The CD133+ 
enriched subpopulation exhibited increased tumorigenic potential when injected 
subcutaneously into NOD/SCID mice, since higher number of tumors were obtained from these 
cells (Table I), and tumor growth was initiated at earlier time points (3 weeks), compared with 
the CD133low population (Table I). IHC analysis demonstrated that the xenografts 
recapitulated the HPAF-II CD133 subpopulation expression levels. Tumors derived from the 
HPAF-II CD133+ subpopulation retained high CD133 expression levels, with limited negative 
cells, while the HPAF-II CD133low xenografts were largely negative for expression of CD133. 
The parental HPAF-II wt-derived xenografts displayed a small percentage of CD133+ cells, 
similar to the original cell line (Fig. 1C). 
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Table I. In vivo tumorigenic assay.  
 Time (weeks)a  
Cell Subpopulation 1 2 3 4 
HPAF II WT 0/5 0/5 0/5 1/5 
HPAF II CD133low 0/5 0/5 0/5 1/5 
HPAF II CD133+ 0/5 0/5 2/5 4/5 
a Data represent the number of animals with tumors vs. the total number of animals injected 
with different cell subpopulations. CD, cluster of differentiation; wt, wild-type. 
 
 
 
 
Figure 1. Validation of the CSC model. (A) Identification of a CSC subpopulation (CD133+ cells) in 
the HPAF-II pancreatic cancer cell line and evaluation of CD133 expression in cell subpopulations sorted 
by flow cytometry. (a) Isotype stained cells were used as controls. (b) HPAF-II cells stained with 
CD133/2-phycoerythrin monoclonal antibody. (B) Enrichment of HPAF-II CD133+ subpopulation 
isolated by magnetic-activated cell sorting represented on a frequency distribution histogram. The 
HPAF-II CD133+ subpopulation exhibits 8.89% of CD133+ cells, while the HPAF-II CD133low 
subpopulation exhibited 3.07% of CD133+ cells, representing an enriched and a depleted population, 
respectively. (C) CD133 expression in HPAF-II tumor xenografts determined by immunohistochemistry 
(magnification, x400). Hemotoxylin and eosin staining was used to reveal the morphology of the tumors 
(magnification, x100). CSC, cancer stem cell; CD, cluster of differentiation; H&E, hematoxylin and eosin; 
SSC-H, measures cell granularity or internal complexity; FH2, phycoerythrin detection; % of Max, % of 
maximum (normalization method). 
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Expression of MUC1 in the CD133+ cell subpopulation 
In order to evaluate the relevance of MUC1 glycoprotein in CD133+ cell biology, the 
expression levels of MUC1 were analyzed in CD133low and CD133+ subpopulations by 
immunoblotting (Fig. 2A). HPAF-II CD133+ cells were highly enriched in MUC1 expression, 
compared with HPAF-II wt and HPAF-II CD133low cells. In addition, MUC1 expression levels 
in the HPAF-II CD133low cell subpopulation were lower than in HPAF-II wt cells (Fig. 2A). 
 
Expression of MUC1 signaling partners in CD133+ cells 
MUC1 function in oncogenic pathways depends on the phosphorylation of its CD by 
several kinases, including EGFR, PKCδ and GSK3β (21). Since it is not possible to assess the 
phosphorylation status of MUC1-CD due to the unavailability of antibodies sensitive to 
phosphorylation, the expression of selected kinases in CD133+ cells was evaluated by 
immunoblot analysis. The results indicated that CD133+ cells were enriched in EGFR and 
PKCδ expression, whereas CD133low cells were enriched in GSK3β expression. The protein 
expression levels of GRB2 were equivalent in HPAF-II wt, HPAF-II CD133+ and HPAF-II 
CD133low cells (Fig. 2B). 
 
 
 
 
Figure 2. Expression of MUC1 and signaling partners. (A) Expression of MUC1 in HPAF-II wt, HPAF-
II CD133low and HPAF-II CD133+ cells was evaluated by western blotting. β-actin was used as a loading 
control. (B) Expression of MUC1 signaling partners (epidermal growth factor receptor, growth factor 
receptor-bound protein 2, protein kinase C delta and glycogen synthase kinase 3 beta) in HPAF-II wt, 
HPAF-II CD133low and HPAF-II CD133+ cells was evaluated by western blotting. β-actin was used as a 
loading control. MUC1, mucin 1; MUC1-CD, mucin 1 cytoplasmic domain; EGFR, epidermal growth 
factor receptor; PKCδ, protein kinase C delta; GSK3β, glycogen synthase kinase 3 beta; GRB2, growth 
factor receptor-bound protein 2; CD, cluster of differentiation; wt, wild-type. 
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MUC1 and β-catenin interaction in the HPAF-II cell line and tumor xenografts 
MUC1-CD contains docking sites for β-catenin, and the interactions between MUC1 and 
β-catenin are known to contribute to the malignant phenotype of tumor cells by modifying the 
expression of target genes in the Wnt signaling pathway (24,29). To assess if MUC1/β-catenin 
interaction was potentiated in CD133+ cells, MUC1 was immunoprecipitated from cell lysates 
of HPAF-II wt, HPAF-II CD133+ and HPAF-II CD133low cells, followed by β-catenin 
immunoblotting. An enrichment in MUC1/β-catenin interaction was observed in HPAF-II 
CD133+ cells. β-catenin expression levels were similar in all conditions (Fig. 3A). 
MUC1/β-catenin interactions in tumor xenografts were confirmed by in situ PLA. 
Significant interactions between MUC1 and β-catenin were observed in HPAF-II wt and HPAF-
II CD133+-derived xenografts, but almost no interactions were observed in HPAF-II CD133low-
derived tumors. The most abundant interactions were observed in the CD133+ tumors (Fig. 
3B). In all cases, the interaction signals were predominantly observed in the nuclei of the cells. 
 
 
 
 
 
Figure 3. Evaluation of MUC1/β-catenin interaction in HPAF-II cells and xenografts. (A) β-catenin 
expression and its interaction with MUC1-CD in HPAF-II wt, HPAF-II CD133low and HPAF-II CD133+ 
cells was evaluated by immunoprecipitation and western blot analysis. β-actin was used as a loading 
control. (B) In situ PLA in tumor xenografts was used to evaluate the interaction between MUC1 and β-
catenin; magnification, (a) x400; (b) x650 (Duolink in situ Detection Reagents Brightfield staining). Brown 
dots correspond to proximity/interaction between MUC1 and β-catenin. Arrows indicate the PLA signals 
in HPAF-II wt tumors. IP, immunoprecipitation; IB, immunoblotting; CD, cluster of differentiation; wt, wild-
type; MUC1, mucin 1; MUC1-CD, mucin 1 cytoplasmic domain; PLA, proximity ligation assay. 
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Discussion 
In the present study, the involvement of CD133 and MUC1 in the highly tumorigenic low-
passage pancreatic cancer cell line HPAF-II, which was derived from the ascites of a 
pancreatic cancer patient, was investigated (30). Using a well-established CD133 selection 
method, an isolated CD133+ cell subpopulation was demonstrated to exhibit features 
associated with CSCs (enhanced tumorigenicity) and concomitant enriched expression of 
MUC1. 
CSCs are known to aberrantly activate canonical signaling pathways (31–33). Recently, 
a MUC1 spliced form was reported to be associated with the differentiation status of stem cells 
(34). In the present study, the expression of MUC1 and oncogenic signaling transducers 
(EGFR, PKCδ, GSK3β and GRB2), as well as the MUC1/β-catenin association, were 
characterized in pancreatic cancer cells that expressed CD133. MUC1-CD, EGFR and PKCδ 
expression levels were increased in the HPAF-II CD133+ subpopulation, while GSK3β 
expression was decreased, and no significant differences were observed regarding GRB2 and 
β-catenin expression levels. These results clearly demonstrate that pancreatic HPAF-II 
CD133+ cells have a distinct expression profile, which includes MUC1 and its associated 
signaling partners, compared with the subpopulation of cells that do not express the stem cell 
surface marker CD133. 
MUC1-CD contains docking sites for molecules such as β-catenin, and the association 
of these proteins is modulated by motifs that may be phosphorylated by several kinases, 
namely EGFR, PKCδ, GSK3β and GRB2 (35). The phosphorylation of MUC1-CD influences 
its interaction with β-catenin, which directly binds at the MUC1-CD motif SAGNGGSSLS 
(22,23). In the present study, increased interactions between MUC1-CD and β-catenin were 
observed in the HPAF-II CD133+ subpopulation, which was correlated with enhanced 
expression of EGFR and PKCδ, and decreased expression of GSK3β (24,36–42). It is known 
that MUC1-CD phosphorylation by EGFR and PKCδ promotes interactions between β-catenin 
and MUC1, while phosphorylation by GSK3β leads to a decrease in this association (39–41). 
It was observed in the present study that EGFR and PKCδ expression were upregulated, while 
GSK3β expression was downregulated, in the HPAF-II CD133+ subpopulation, compared with 
the HPAF-II CD133low subpopulation, which likely explains the observed increase in MUC1-
CD/β-catenin interactions in the CD133+ subpopulation, despite the fact that the steady-state 
levels of β-catenin remained unchanged in these cells. 
The interactions between MUC1-CD/β-catenin influence several tumorigenic processes. 
Binding of MUC1-CD to β-catenin suppresses the capacity of β-catenin to interact with E-
cadherin at adherens junctions, resulting in the loss of cell-cell adhesion, thus playing a 
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relevant role in tumor invasion (43). The MUC1-CD/β-catenin complex contributes to β-catenin 
stabilization by blocking its GSK3β-mediated phosphorylation and consequently its 
degradation in the proteasome (24). Furthermore, MUC1-CD/β-catenin is translocated to the 
nucleus, where it may enhance the activity of β-catenin in association with TCF/LEF 
transcription factors, thus promoting cell proliferation and survival through upregulation of the 
transcription of Wnt target genes (36–38,42). Recently, this process has been associated with 
a metastatic gene expression signature and an epithelial-to-mesenchymal transition 
phenotype of tumor cells (44). In the present study, the results of in situ PLA for tumor 
xenografts revealed that CD133+ tumors exhibited frequent MUC1-CD/β-catenin interactions, 
with the MUC1-CD/β-catenin complex being mainly present in the cellular nuclei, where it 
presumably binds to transcription factors and activates the transcription of genes involved in 
cell proliferation and survival. 
In summary, the present study has demonstrated for the first time that pancreatic CD133+ 
cells display enhanced expression of MUC1 and its associated signaling partners. CD133 and 
MUC1 expression are associated with an aggressive tumor phenotype, partly through the 
production of enhanced MUC1-CD/β-catenin interactions, and this may partly explain the 
behavior of pancreatic CSCs. 
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Abstract 
MUC1 is a heavily glycosylated transmembrane glycoprotein normally expressed at low 
levels in the apical surface of epithelial cells and overexpressed in more than 80% of pancreatic 
tumors. MUC1 overexpression is well known to be correlated with tumor initiation, tumor 
progression and poor survival of cancer patients. The MUC1 gene encodes a protein with a 
large extracellular domain with a tandem repeat region, a self-cleaving domain, a 
transmembrane domain and a highly conserved cytoplasmic domain (MUC1-CD) that 
participates in several oncogenic signaling pathways. MUC1 isoforms, generated by 
alternative splicing events, have been differentially associated with carcinogenic processes 
and their functional significance remains largely unknown.  
The main objective of this work was to study the relevance of the MUC1/S2 splice variant 
in pancreatic carcinogenesis using an in vitro model based on a transformed pancreatic cell 
line, transduced using a lentivirus system, with MUC1/S2 splice variant and MOCK construct. 
To achieve this goal, we evaluated the impact of the expression of this splice variant in 
proliferation, migration and invasion of the generated cells. Moreover, we evaluated the 
subcellular localization of MUC1/S2 and its interaction with p53 protein. It was possible to 
observe that MUC1/S2 expression is mostly restricted to the cytoplasm and leads to an 
increase in the invasive phenotype of these cells. Interestingly, we identified for the first time 
an interaction between MUC1/S2 and p53 protein, which can indicate a role of this isoform in 
signaling pathways. No changes were detected in proliferation and migration of the transduced 
cells. We validated the use of our model to study MUC1 splice variants and provided some 
insights to disclosure MUC1/S2 biological function in pancreatic carcinogenesis. 
 
 
Introduction 
Mucin 1 (MUC1) is a transmembrane glycoprotein heavily O-glycosylated and expressed 
in the apical surface of epithelial cells of the mammary gland, prostate, stomach and pancreas, 
among others, providing protection to the epithelium from pathogens colonization, dehydration, 
changes in pH and degradative enzymes (1-3). The mature MUC1 protein encompass two 
subunits, the extracellular N-terminal subunit that comprises the signal sequence and the 
variable number tandem repeat (VNTR) domain, and the C-terminal subunit that comprises an 
extracellular stem region, a short transmembrane domain and the cytoplasmic domain (MUC1-
CD) (4-6). This glycoprotein is synthesized as a single polypeptide chain being 
autoproteolytically cleaved in the endoplasmic reticulum soon after synthesis and is present, 
in normal conditions, on the cell surface as a heterodimer (7, 8). The cleavage of MUC1 
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precursor polypeptide occurs between the glycine and serine residue of the GSVVV motif 
within the SEA (sea urchin sperm protein, enterokinase, and agrin) module of the extracellular 
domain (8-10). In the membrane, the two subunits bind together by a strong non-covalent 
interaction (4). MUC1 is heavily O-glycosylated mostly in the VNTR region and despite N-
glycosylation also being present it is much less frequent. The glycosylation profile of MUC1 is 
dependent on the tissue and on the glycosyltransferases expressed in the tissue (11, 12). 
MUC1, together with other mucins, plays a central role in maintaining homeostasis and 
promoting cell survival in response to harsh environments. In normal conditions MUC1 
functions as a cell-surface receptor and sensor, triggering cell signaling responses to external 
environment through post-translational modification of the cytoplasmic tail. 
MUC1 is overexpressed and aberrantly glycosylated in a diversity of epithelial cancers, 
being correlated with tumor initiation, tumor progression and worse outcome of cancer patients 
(13-15).  Pancreatic cancer (PC) is one of the deadliest cancer-related diseases worldwide 
with almost no changes in survival rates being achieved in the last decades and MUC1 is 
overexpressed in more than 80% of these tumors. 
Most efforts in MUC1 research have focused on the full MUC1 protein and its role in cancer 
initiation and progression. However, MUC1 undergoes alternative splicing events that give rise 
to different isoforms which can play different biological roles. 
Alternative splicing is a key process in the regulation of gene expression contributing to 
the heterogeneity of the transcriptome and proteome and is estimated to occur in over 95% of 
all multiple-exon human genes. This mechanism generates multiple mRNAs from a single 
gene during pre-mRNA maturation and results in a variety of different proteins that differ in 
their aa sequence. Alternative splicing has been associated with a large number of diseases, 
including cancer (26). MUC1 gene comprises seven exons and six introns and a variety of 
isoforms can be generated by alternative splicing, intron retention and exon skipping. The best 
characterized MUC1 isoform is the polymorphic mucin-like type 1 transmembrane protein, 
MUC1/REP or MUC1/TM, which represents the full molecule. Although more than 70 isoforms 
have been identified so far, the full-length sequence has only been reported for some. 
MUC1/SEC, a secreted truncated isoform, retains the VNTR region and is devoided of the 
transmembrane and cytoplasmic regions being mostly associated with absence of malignancy. 
This isoform was identified as being secreted by several different cells, like benign ovarian 
tumors, and is present in the sera of breast cancer patients and in human milk (27, 28). 
Recently, 78 different MUC1 isoforms were isolated from human cervical (HeLa) and breast 
cancer (MCF7) cell lines, T-cell leukemia Jurkat cells and from human activated T cells, being 
MUC1/A, MUC1/B, MUC1/C, MUC1/D, MUC1/X, MUC1/Y and MUC1/ZD the more abundant 
ones (29). This study identified exon 2, which contains the VNTR region, as the most skipped 
exon among all different isoforms using the same 5’ splice site and variable 3’ splice sites. On 
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the other hand, MUC1-CD region remains unchanged in almost all MUC1 short isoforms, 
allowing them to keep the important signaling function (29). 
Different splice variants are involved in epithelial to mesenchymal transition (EMT) 
induction, resistance to standard chemotherapy agents as well as being described as accurate 
markers of pluripotency in human embryonic stem cells (6, 30, 31).  
MUC1/S2 isoform was identified in human cervical (HeLa) and breast cancer (MCF7) cell 
lines and is absent in T-cell leukemia Jurkat cells and human activated T cells (29). This splice 
variant has a retention of 27bp of intron I and excision of 659bp from exon 2 and total excision 
of exons 3, 4 and 5, lacking the transmembrane domain and cleavage site of the SEA domain. 
Despite a few reports showing the involvement of MUC1 isoforms in cell biology, the functional 
significance of each of these spliced variants is not yet well understood.  
In this work we intended to disclosure the role of MUC1/S2 splice variants in the phenotype 
of pancreatic cancer. 
 
 
Material and Methods 
Cellular model and culture conditions 
The cell line model used in this work is based on the hTERT-THPNE cell line (THPNE), a 
transformed cell line derived from a non-tumorigenic epithelial hTERT-HPNE cell line isolated 
from a normal pancreatic duct and immortalized with the catalytic subunit of telomerase (32, 
33). THPNE cell line was generated, as described by Campbell and colleagues, by sequential 
retroviral mutant K-Ras (G12D), E6/E7, and SV40 small t antigen transduction in order to mimic 
some of the oncogenic modifications present in the currently accepted pancreatic cancer 
progression model (32, 34). Afterwards, we transduced THPNE cell line with MUC1/S2 splice 
variant cDNA sequence (AY327584) based on pLVX-EF1α-IRES-Puro vector (Clontech). The 
control was performed using an empty pLVX-EF1α-IRES-Puro vector (MOCK). The efficiency 
of the transduction was confirmed by Western blot and immunofluorescence. 
To establish a MUC1/S2 stable clone we performed limited dilutions from a transduced cell 
population. Generated cell lines were cultured in 75% low-glucose Dulbecco´s Modified Eagle 
Medium (DMEM) (Gibco) supplemented with 25% M3F medium (INCELL Corporation LLC, 
TX), fetal bovine serum (FBS) (Gibco) at a final concentration of 5%, 50 mg/ml gentamicin 
(Invitrogen) and 10ng/ml human EGF. Cells were grown at 37ºC with 5% CO2 in a humidified 
atmosphere. 
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Lentivirus production and transduction 
MUC1/S2 splice variant and MOCK vector were co-transfected into 293FT (Life 
Technologies) cell line using ViraPower Packaging Mix (Life Technologies) according to 
manufacturer’s recommendations. 293FT cell line was grown in DMEM supplemented with 
10% FBS and 50 mg/ml gentamicin. After 24 and 72 hours, lentivirus particles were harvested 
and THPNE cell line incubated with the respective lentivirus particles containing the MUC1/S2 
splice variant and MOCK. After overnight incubation, media with the lentivirus was removed 
and fresh media was added. 
 
Protein extraction and Western blot 
Expression levels of MUC1 were evaluated by western blot. After washing cells twice with 
PBS, lysis buffer (10mM Tris pH 7.4, 150mM NaCl, 0.1% (p/v) SDS, 1mM PMSF, 1% (v/v) 
Triton X-100) was added and cells were scraped. Lysates were incubated on ice for 1 hour 
and centrifuged for 30 minutes at 4ºC to collect the supernatants. Protein content was 
assessed by the BCA Protein Assay Kit (BioRad), according to the manufacturer’s 
recommendations. 
Protein extracts were analyzed in a 10% SDS-PAGE (Invitrogen), transferred to a PVDF 
membrane (Amersham Biosciences) and blotted overnight at 4ºC with MUC-1 Ab-5 Mab 
(diluted 1:300, NeoMarkers). After three washes with PBS-0.1%Tween 20, goat anti-hamster 
peroxidase conjugated antibody (1:2000, DAKO) in 5% non-fat milk (PBS-0.1%Tween20) was 
added. Proteins were visualized using an enhanced chemiluminescence detection kit 
(BioRad). 
 
Immunofluorescence  
To assess transduction efficiency, immunofluorescence was performed by culturing cells in 
plastic coverslips until confluency. After this step, they were washed once in PBS-1% and fixed 
for 15 minutes at room temperature (RT) in 4% paraformaldehyde and 120mM sucrose. The 
cells were then incubated for 15 minutes with 0.1M glycine in order to neutralize residual 
paraformaldehyde and permeabilized for 15 minutes with 1% BSA/0.1% Triton X-100 in PBS. 
After three washes in PBS, the primary antibody, MUC-1 Ab-5 Mab, against MUC1 cytoplasmic 
tail (that is present in MUC1/S2 isoform) was incubated for 1 hour at RT. Cells were washed 
in PBS and incubated with DyLightTM 488-conjugated AfiniPure Goat anti-armenian hamster 
(Jackson ImmunoResearch) for one hour in the dark at RT. After washing, slides were mounted 
in Vectashield/DAPI (Vectorlabs) and images acquired by confocal microscopy. 
For the MUC1/S2 isoform specific organelle localization study the same 
immunofluorescence protocol was used and the primary antibodies against proteins specific 
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for each organelle were incubated together with MUC-1 Ab-5 Mab overnight at 4ºC. The 
antibodies used were: anti-COX IV protein for the mitochondria (1:300,3E11, Cell Signaling), 
anti-Calveolin for the Endoplasmic reticulum (1:300, Caveolin-2 (D4A6), Cell Signaling), Anti-
Golgi Complex for the Golgi apparatus (1:300, Anti-Golgi Complex (ab103439), abcam) and 
anti-LAMP1 protein for the Lysosomes (1:200, LAMP1 (D2D11), Cell Signaling). MUC1 
secondary antibody used was DyLightTM 488-conjugated AfiniPure Goat anti-armenian 
hamster (green color) and Alexa Fluor® 594-conjugated Goat anti-rabbit was used for specific 
cell compartments (red color). Co-localization levels (shown as yellow spots) were evaluated 
as a percentage of co-localization in a specific compartment compared with overall expression 
levels (100%) of MUC1/S2 isoform in the cell. 
 
Brdu assay 
In order to evaluate cell proliferation, we performed bromodeoxyuridine (Brdu) incorporation 
assay according to manufacturer’s recommendations. Briefly, 1.0x104 cells/well for stable 
clones were seeded in coverslips on 6-well plates (four replicates each) for 72 hours. Cells 
were incubated at 37ºC with 5% CO2 in a humidified atmosphere and after the incubation 
period the medium was removed and cells incubated with 10µM BrdU for 1 hour under the 
same conditions. Afterwards, a standard immunofluorescence protocol using a primary 
antibody anti-BrdU (Clone Bu20a; Dako) was performed. The number of BrdU incorporated 
cells was determined on a fluorescence microscope. 
 
Wound healing assay 
In order to address differences in cell migration we seeded 20x104 cells/well in 6-well plates 
and a wound was performed 12 hours after seeding. Cells were imaged every 10 min at 37°C 
in an atmosphere of 5% CO2, 95% air for 9 hours by time-lapse microscopy. Measurements of 
wound closure were calculated as Distance t0 − Distance t9h.  
 
Matrigel invasion assay 
Cell invasion was assessed using BD BiocoatTM MatrigelTM invasion chambers, 8µm PET 
membrane (BD Biosciences). Cells were seeded in triplicate at 3.0x104 cells/insert (24-well 
plates) in FBS free medium and 20% FBS containing medium was added to the bottom of the 
growth well, as an attractant. After 22 hours incubated at 37ºC with 5% CO2 in a humidified 
atmosphere, non-invading cells were removed with the help of a cotton swab and the invading 
cells fixed in methanol for 15 minutes. Membranes were removed from the insert and mounted 
in a slide with Vectashield/DAPI. Invading cells were counted under a fluorescence 
microscope. Data is expressed as a ratio between invasive cells in control and clone. 
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In situ Proximity Ligation Assay (PLA) 
Proximity ligation assay was used to assess the close proximity (and possible interaction) 
between MUC1-CD and p53 using the DuoLink II fluorescence kit (Olink®Bioscience, Sweden) 
according to the manufacturer’s instructions. Cells were grown in slides until confluent, fixed 
in methanol for 15 minutes, permeabilized for another 15 minutes and incubated overnight at 
4 °C with MUC-1 Ab-5 Mab (diluted 1:200, NeoMarkers), and/or anti-p53 Ab-2 Mab (diluted 
1:100, Santa Cruz Biotechnologies). Slides were washed with PLA wash buffer and incubated 
with PLA probe anti-mouse MINUS and anti-hamster directly conjugated with PLA probe Plus 
(previously labeled using Duolink II Probemarker Plus (OLink Bioscience), according to the 
manufacturer’s instructions), followed by a 1 hour incubation at 37ºC in a humidity chamber. 
Following washing steps, ligation and signal amplification was performed using Duo-Link II 
Detection Reagent Orange according to the manufacturer’s instructions (Olink Bioscience). 
Slides were mounted in vectorshield/DAPI Mounting Media and observed using Zeiss LSM 
510 confocal microscope. Results are shown like bright red dots and quantified using ImageJ 
software. 
 
Statistical analyses 
Statistical analyses were performed using Graphpad Prism 4.0 software (Graphpad 
software Inc.). Data are present as mean ± SD. Differences in the mean of samples were 
analyzed with the student´s t test. Differences under 0.05 were considered significant and 
indicated with a *. 
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B 
Results 
In this work we have investigated the role of the MUC1/S2 isoform in a pancreatic cancer 
model generated as briefly described in Material and Methods. Figure 1 shows the expression 
levels of MUC1 in THPNE Mock and THPNE/S2 both by immunofluorescence (A) and Western 
blotting (B). MUC1 levels are undetectable in the MOCK cell and in the MUC1/S2 clone it is 
possible to observe expression in 100% of the cells, mainly in the cytoplasm.   
  
 
Figure 1. MUC1 expression in THPNE MOCK and THPNE MUC1/S2 transduced cells. Confirmation 
of MUC1 splice variant overexpression was performed by immunofluorescence (A) and Western blotting 
(B), both using a MUC1-CT2 antibody against MUC1 cytoplasmic tail. For western blotting (B) β-actin 
was used as a control for protein loading. 
 
We further studied the subcellular localization of MUC1/S2 isoform, using 
immunofluorescence co-localization study (Figure 2). We performed double 
immunofluorescence using an anti-MUC1 antibody and specific antibodies for mitochondria 
(anti-COXIV), Golgi apparatus (anti-Golgi Complex), endoplasmic reticulum (anti-Calveolin) 
and lysosomes (anti-LAMP1) and estimated the percentage of co-localization. The results 
obtained indicate that MUC1/S2 is present in all subcellular localizations to different degrees. 
More specifically, around 10% of MUC1/S2 expressed protein localizes in the mitochondria, 
5% in the golgi apparatus, 25% in the endoplasmic reticulum and 10% in the lysosomes.   
A 
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Figure 2. MUC1 localization within different cellular organelles by immunofluorescence confocal 
microscopy. The results represent the percentage of MUC1/S2 that co-localizes with specific proteins 
of each cell organelle. 
 
 
We next analyzed the impact of MUC1/S2 splice variant de novo expression in this 
pancreatic cancer model using proliferation, migration and invasion assays. No differences 
were found in proliferation, determined by the BrdU assay, or migration, determined with the 
wound healing assay, when comparing MUC1/S2 transduced cells with the control (Figure 3).  
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Figure 3. Cell proliferation and migration assay. (A) Cell proliferation analysis by the 5-Bromo-
2'-deoxyuridine (BrdU) incorporation assay. Results are expressed as mean ± SD from three 
independent experiments. (B) Cell migration analysis by wound healing In vitro assay. Results are 
expressed as mean ± SD from three independent experiments evaluated 9h after wound.  
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To explore whether MUC1/S2 splice variant plays a role in the invasion capacity of the cells 
we performed a matrigel invasion assay (Figure 4). The results show that the presence of the 
MUC1/S2 splice variant significantly increases the invasion capacity of THPNE cells (P<0.05).     
   
 
 
 
 
 
 
 
 
Figure 4. Matrigel invasion assay. Results are expressed as mean ± SD from three independent 
experiments. *, P<0.05; (Student's t-test). 
 
Finally, we evaluated if the MUC1/S2 isoform retains the capacity to interact with p53 
protein, which is known to be involved in MUC1 signaling (Figure 5). Using PLA technique, we 
observed an interaction between MUC1/S2 and p53, mostly in the cytoplasm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. MUC1 – p53 interaction evaluation by proximity ligation assay (PLA). Results are 
expressed as mean ± SD from three independent slides. 
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Discussion 
Pancreatic cancer remains a dismal disease for the vast majority of the patients 
representing a huge challenge both in research and in the clinical field, worldwide. Despite the 
efforts, conventional therapeutic approaches that include surgery, radiation, chemotherapy 
and even combinations of these have shown little impact on the progression of the disease. 
Facing this, the understanding of pancreatic molecular biology to address a better diagnosis, 
prevention and treatment is crucial. In this study, we aimed to determine the involvement of 
the MUC1/S2 splice variant in pancreatic carcinogenesis. To achieve this goal an in 
vitro model based on a transformed pancreatic cell line was used, transduced using a lentivirus 
system, with MUC1/S2 splice variant and MOCK construct. 
We started by analyzing the expression level of MUC1 in the transduced cells. As a specific 
antibody for MUC1/S2 is not available, we used a primary antibody against MUC1 cytoplasmic 
tail (MUC-1 Ab-5 Mab) that is also present in MUC1/S2 isoform. It is possible to observe that 
100% of the THPNE MUC1/S2 cells are expressing the transduced isoform and the expression 
is mostly restricted to the cytoplasm where it can be associated with other proteins playing a 
role in cell signaling (24). It is also possible to observe MUC1/S2 expression in the nuclei of 
the cells, but at much lower levels. MUC1/S2 localization in the nuclei indicates that although 
not having the cleavage region, MUC1/S2 is capable of translocation to the nuclei which points 
towards their participation in the modulation of transcriptional events that are involved in 
malignant progression, namely invasion and metastasis formation in response to, for example, 
Wnt/β-catenin or STAT pathways activation (13, 35). MUC1/S2 isoform is not present at the 
cell membrane, the normal cell localization of MUC1, which is expected, as this MUC1 isoform 
doesn’t encompass the transmembrane domain. Therefore, biological processes related with 
membrane MUC1 localization such as interaction with EGFR, Erb2 and others RTKs 
contributing to activation of different pathways such as mitogen-activated protein kinase 
(MAPK) pathway in response to external environment are not expected to be activated by this 
MUC1 splice variant (18). MUC1 basal levels in THPNE MOCK cell line are undetectable, 
which validates our model for studying the impact of MUC1 splice variants. 
To understand MUC1/S2 isoform distribution on the cell, which can give us an indication of 
its biological function, we performed a co-localization study. We evaluated its possible 
localization in the mitochondria, golgi apparatus, endoplasmic reticulum and lysosomes. We 
identified around 50% overall expressed protein in the cell compartments studied. Of these, 
the majority (around 25%) localizes in the ER. Endoplasmic reticulum has a central role in 
protein biosynthesis, determining the correct folding of a protein which affects its function and 
cellular localization and even if the protein will be secreted. Post-translational modifications, 
such as N-glycosylation, are processes that take place in ER and can be occurring to 
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MUC1/S2, explaining the observed 25% localization of MUC1/S2 protein in the ER. Due to the 
relevance of mitochondria in apoptosis, and the relevance of this process in carcinogenesis, it 
is important to further study MUC1/S2 presence in this subcellular compartment (around 10%). 
The additional 50% expressed protein are probably in the nuclei of the cell and in another 
compartments of cell cytoplasm like exosomes. Further studies are necessary to better 
understand the subcellular localization of this protein. 
   After evaluating the expression pattern and subcellular localization, we analyzed the 
impact of MUC1/S2 isoform in proliferation and migration, as they are relevant features 
associated to tumor cells in which full MUC1 is known to be involved. No differences were 
observed between THPNE MUC1/S2 and THPNE MOCK cell lines. Afterwards, we performed 
an invasion assay to analyze the possible involvement of the studied protein. MUC1/S2 
overexpression led to an increased invasion of THPNE pancreatic cancer cells. The 
involvement of full MUC1 in invasion is documented and one of the described mechanisms 
show that once translocated to the nucleus MUC1 is capable of repressing E-cadherin 
expression and induce expression of EMT inducers such as Snail and Slug (23). Finally, we 
tried to understand if MUC1/S2 isoform retains the capacity to interact with p53 protein, which 
is known to be involved in MUC1 signaling. p53 is a major tumor suppressor gene involved in 
DNA repair, apoptosis, cell cycle arrest among others and is mutated in over 50% of human 
cancers (36). We observed an interaction between MUC1/S2 and p53, mostly in the cytoplasm. 
This interaction was described, in the nucleus, as contributing to the regulation of p53-
responsive genes, namely, activation of p21 and repression of Bax transcription, two proteins 
involved in cell-cycle progression and apoptosis (37). There are no studies showing the 
relevance of the interaction between MUC1 and p53 in the cytoplasm. 
In conclusion, we validated the use of an in vitro model based on a transformed pancreatic 
cell line transduced with a MUC1 splice variant to study its relevance in pancreatic 
carcinogenesis. We evaluated the expression pattern of MUC1/S2 splice variant and its impact 
in proliferation, migration and invasion of the generated cells. Moreover, we assessed the 
subcellular localization of MUC1/S2 and its interaction with p53 protein. We observed that 
MUC1/S2 expression is mostly restricted to the cytoplasm and leads to an increase in the 
invasive phenotype of these cells. Excitingly, we identified for the first time an interaction 
between MUC1/S2 isoform and p53 protein, which function remains to be uncovered.
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Abstract  
Mucin 1 (MUC1) has been described as the renaissance molecule due to the large set of 
functions it displays in both normal and neoplastic cells. This membrane-tethered glycoprotein 
is overexpressed and aberrantly glycosylated in most epithelial cancers, being involved in 
several processes related with malignant phenotype acquisition. With a highly polymorphic 
structure, both in the polypeptide and glycan counterparts, MUC1 variability has been 
associated with susceptibility to several diseases, including cancer. Biochemical features and 
biological functions have been characterized upon the full-length MUC1 protein, remaining to 
clarify the real impact on cell dynamics of the plethora of MUC1 isoforms. This review aims to 
encompass a detailed characterization of MUC1 role in carcinogenesis, highlighting recent 
findings in cell differentiation and uncovering new evidences of MUC1 isoforms involvement in 
malignant phenotype.  
 
Mucins 
Mucins (MUC) are large and heavily O-glycosylated proteins generally expressed in the 
apical surface of epithelial cells being the major compound of the mucus. They are present in 
relatively harsh environments like the digestive and respiratory tracts and in the secretory 
epithelia of different organs such as the kidney, liver and pancreas (1). Mucin canonical 
functions are to provide protection from pathogens, dehydration, changes in pH and 
degradative enzymes. All mucins contain proline, threonine and serine (PTS)-rich tandem 
repeat domains that are heavily O-glycosylated in serine and threonine residues and contribute 
up to 50–80% of the glycoprotein total molecular weight (2). The specific sequence and the 
number of tandem repeats are variable among different mucins and individuals, due to genetic 
polymorphisms. N-glycosylation is also often present, although to a much lesser degree. The 
human MUC gene family encodes for up to 22 known proteins that can be divided in two main 
groups: secreted and membrane-associated mucins. Secreted mucins are subdivided in the 
gel-forming mucins (MUC2, MUC5AC, MUC5B, MUC6 and MUC19) and non-gel-forming 
mucins (MUC7) (3–7). Gel-forming mucins are typically expressed in specialized glands or 
goblet cells and their main function is to create the three-dimensional network of mucus, 
contributing for its viscoelastic properties through oligomerization domains, in order to protect 
the epithelium against different injuries (8). On the other hand, non-gel-forming mucins are 
smaller and unable to oligomerize, being mostly secreted by salivary and lachrymal glands (3, 
9). 
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Membrane-associated mucins (MUC1, MUC3A, MUC3B, MUC4, MUC11, MUC12, 
MUC13, MUC15, MUC16, MUC17, MUC20, MUC21 and MUC22), in addition to their function 
in protection of the epithelia from adverse conditions, also play important biological roles in 
cell-cell and cell-extracellular matrix interaction and signal transduction (10, 11). They are 
anchored at the cell membrane through a single hydrophobic transmembrane (TM) domain 
and, with the exception of MUC4, all of them contain a SEA (Sea urchin sperm protein, 
Enterokinase and Agrin) domain in the extracellular region (10). The expression profile of 
mucins as well as the glycosylation pattern is tissue- and cell type-specific and can be modified 
with cellular differentiation state or under pathologic conditions such as tumorigenesis. 
 
Mucin 1 
Structure and normal function  
Mucin 1 (MUC1; also known as episialin, PEM, H23AG, EMA, MCA and CA15-3 among 
others) was the first mucin to be cloned and until now remains the best studied protein of this 
family. MUC1 is a membrane-associated mucin, normally expressed at basal levels in almost 
all epithelial tissues, being found in most human organs, namely, the esophagus, stomach, 
liver, pancreas, breast, lungs or kidney (12). Moreover, it was also described in hematopoietic 
and human embryonic stem cells (hESCs) as well as in stem/progenitor breast cells (13–16). 
MUC1 is normally expressed at the apical surface of polarized epithelial cells in relatively harsh 
environments like the digestive and respiratory tracts to provide protection from pathogens, 
dehydration, changes in pH and degradative enzymes, functions that are enhanced by its 
extensive glycosylation. 
MUC1 gene is located on the long arm of chromosome 1 in position 21 (locus 1q21), and 
comprises seven exons ranging about 4.4 kb. The mature MUC1 protein encompasses two 
subunits, the extracellular N-terminal alpha subunit and the mainly intracellular C-terminal beta 
subunit. The N-terminal subunit contains the important signal peptide that localizes the mature 
protein to the apical membrane and the variable number tandem repeat (VNTR) domain. On 
the other hand, the C-terminal subunit is composed of an extracellular stem region of 58 amino 
acids (aa), a short transmembrane domain with 28 aa and the cytoplasmic domain (MUC1-
CD) with 72 aa (Fig. 1) (17, 18). The VNTR region consists of a serine and threonine-rich highly 
polymorphic region composed by closely identical sequences of 20 amino acid (aa) repeated 
25 to 125 times, being the most common the PAHGVTSAPDTRPAPGSTAP sequence (17). 
The variable number of VNTRs and their content of Ser/Thr residues can be markedly different 
among individuals and is associated with different susceptibility to several diseases, including 
cancer and precursor lesions (19–21). 
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MUC1 is synthesized as a single polypeptide chain being autoproteolytically cleaved in 
two subunits (alpha (α) and beta (β)) in the endoplasmic reticulum soon after synthesis and is 
present, in normal conditions, on the cell surface as a heterodimer (22, 23). During MUC1 
folding, the cleavage of the precursor polypeptide occurs between glycine and serine residues 
of the GSVVV motif within the SEA module of the extracellular domain (22, 24, 25). MUC1 
core protein has a molecular weight of 120–225 kDa which changes to 250–1000 kDa with 
glycosylation and, in the membrane, the subunits α and β bind together through a strong non-
covalent interaction (26, 27). Identical to other mucins, MUC1 is mostly  O-glycosylated 
showing fewer N-linked glycans. Serine and threonine residues are the targets of O-linked 
glycosylation and in the VNTR region each sequence contains up to five glycosylation sites. 
The glycosylation profile of MUC1 is dependent on the tissue and on the profile of 
glycosyltransferases expressed (28, 29). MUC1, like other membrane-associated mucins, 
besides playing a central role in maintaining homeostasis and promoting cell survival in 
response to harsh environments, is also involved in cell signaling transduction events mostly 
through MUC1-CD phosphorylation. MUC1-CD, a highly conserved 72 aa sequence, contains 
several Tyr residues that represent potential docking sites for proteins with SH2 domains, such 
as protein kinase C δ (PKCδ), glycogen synthase kinase 3β (GSK-3β), ErbB receptors like 
ErbB1/epidermal growth factor receptor (EGFR) and some family members of c-Src non-
receptor tyrosine kinases Lyn and Lck (30–32). ZAP-70 tyrosine kinases are also responsible 
for MUC1-CD phosphorylation in response to T-cell activation (33). The serine, threonine and 
tyrosine residues of MUC1-CD represent potential phosphorylation sites and changes in the 
phosphorylation status of MUC1-CD can modulate its affinity for mediators of signal 
transduction, including β-catenin and p53 proteins (Fig. 1) (34, 35). 
 
 
Fig. 1. MUC1 structure with sequence of cytoplasmic domain and putative binding sites. (A) N-
terminal subunit and C-terminal subunit forming a stable heterodimeric complex at the cell membrane. 
(B) Amino acid sequence of MUC1 cytoplasmic domain (MUC1-CD), showing potential phosphorylation 
sites and protein-binding motifs. 
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MUC1 alterations and function in cancer 
MUC1 is one of the most deregulated mucins during carcinogenesis being overexpressed 
in most human epithelial cancers and hematologic malignancies. In tumor cells, MUC1 
displays new biochemical features, cellular distribution and functions. 
MUC1 is overexpressed in tumors due to several mechanisms including increased 
transcription, amplification of MUC1 genomic locus or loss of post-transcriptional regulation 
(36–39). In tumor cells, MUC1 has fewer, shorter and less branched glycans which is in 
contrast with normal cells that normally show more elongated and highly branched glycans 
(40). The hypoglycosylation of MUC1 in cancer cells impacts on the stability and the subcellular 
localization of the protein increasing intracellular uptake by clathrin-mediated endocytosis. As 
a consequence, and since MUC1 degradation is not increased, there is an intracellular 
accumulation of this protein (41). MUC1 glycosylation has also been associated with 
inflammatory response since its dense glycan component entraps proinflammatory factors 
such as transforming growth factor α (TGF-α), interleukin 1 (IL-1) and IL-4, among others, that 
are released after MUC1-N shedding, inducing an inflammatory response (42). Due to the loss 
of polarity in tumor cells, MUC1 is no longer restricted to the apical surface and covers the 
entire cell surface. This loss of polarity disturbs cell-cell and/or cell-matrix interactions favoring 
the release of tumor cells into the blood circulation and enabling the interaction between MUC1 
and other membrane proteins normally expressed in the basolateral domain of the cells such 
as growth factor receptors (43). Interactions with these proteins can contribute to growth and 
survival of tumor cells through activation of signaling pathways or by blocking the access of 
other molecules to these receptors (Fig. 2) (44). 
 
Fig. 2. MUC1 properties and subcellular localization. MUC1 is confined to the apical surface of 
normal epithelial cells. However, in tumor cells, this polarity is lost and no longer restricted to the apical 
surface covering instead the entire cell surface, which potentiates the interaction between MUC1 and 
receptor tyrosine kinases (RTKs). These interactions could contribute to signaling pathway activation or 
repression by blocking the access of other molecules to these receptors. Hypoglycosylation of MUC1 is 
also a feature in cancer cells. 
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Although the non-consensual recognition of MUC1 as an oncogene, its involvement in 
proliferation, angiogenesis, invasion and metastization is now well documented. Studies in 
transgenic mice and in different cell lines have related MUC1 with carcinogenesis in multiple 
ways. It has been hypothesized that, globally, MUC1 participates in the control of local 
microenvironment allowing the tumor to adapt, survive and proliferate in challenging contexts 
during invasion and metastasis. MUC1 does not have a DNA binding domain but interacts 
directly with a diversity of transcription factors making part of transcriptional complexes and 
promoting their specificity. This regulation is significantly modulated by MUC1-CD 
modifications (23, 45, 46). The discovery that overexpression of MUC1-CD alone is sufficient 
to induce anchorage independent growth and tumorigenicity of carcinoma cells in vitro led to 
a stronger focus on the study of this MUC1 subunit (47). MUC1-CD signaling at the cell 
membrane is triggered by phosphorylation of the serine and threonine residues. This 
phosphorylation can occur in response to the activation of several surface growth factor 
receptors, namely, platelet-derived growth factor receptor (PDGFR) and members of the Erb 
family which include EGFR and ErbB2/Her2 (43, 45, 48). MUC1-CD works as a docking site 
for the activation of different signaling pathways important in cellular proliferation, 
differentiation, migration and survival such as PI3K and mitogen-activated protein kinase 
(MAPK) pathways (49). MUC1-CD is also a target of several different kinases including the 
PKCδ, GSK3β and the tyrosine kinases c-Src and Lck (50). Phosphorylation events regulate 
the interaction between MUC1-CD and other intracellular binding partners such as effectors of 
the Wnt pathway or β-catenin (30, 51, 52). MUC1 and β-catenin do not interact in a normal 
polarized epithelium since they have different subcellular localizations. β-catenin binds to 
MUC1-CD through a motif similar to those present in E-cadherin and in the adenomatous 
polyposis coli (APC) protein, at the SSSL sequence (52). This interaction is dependent of 
MUC1-CD phosphorylation by c-src kinase and is inhibited by GSK3β phosphorylation (30). 
MUC1-CD/β-catenin complex leads to an accumulation of β-catenin in the cell nuclei where it 
acts as a transcriptional coactivator of genes controlling cellular growth such as cyclin D1 and 
c-myc, promoting tumor progression (53). Importin β and nucleoporin Nup62 are the mediators 
of MUC1-CD nuclear translocation (54). Moreover, MUC1-CD/ β-catenin interaction decreases 
the ability of β-catenin to interact with E-cadherin at adherens junctions leading to a decrease 
in cell-cell interaction (55). β-catenin in the nucleus also represses E-cadherin expression and 
increases the transcription of epithelial-mesenchymal transition (EMT) inducers such as Snail, 
Slug, Vimentin and Twist, enhancing the invasive potential of tumor cells (56, 57). EMT is also 
induced by MUC1 through regulation of miRNAs involved in EMT-gene expression (58, 59).  
Angiogenesis is another hallmark of cancer in which MUC1 plays a role. The growth of the 
tumor mass creates a low oxygen and nutrient microenvironment (hypoxia) that induces tumor 
cells to express proangiogenic factors, promoting growth of new vessels in order to adapt and 
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survive in this environment. It has been demonstrated that MUC1 stimulates the expression of 
proangiogenic factors like connective tissue growth factor (CTGF), platelet-derived growth 
factor subunit B (PDGF-B) and vascular endothelial growth factor A (VEGF-A), that are 
responsible for the synthesis of new blood vessels within the tumor (60). In pancreatic cancer, 
it was also reported that MUC1 overexpression induces the synthesis and secretion of VEGF 
through the AKT signaling pathway (61). Due to the loss of apical-basal expression restriction, 
in cancer MUC1 regulates the cell metabolite flux at several levels. These metabolic alterations 
provide tumorigenic features to the tumor cells such as proliferation and metastasis formation 
(62). MUC1 is involved in glycolysis regulation through the PI3K/Akt pathway that induces 
expression of glucose transporters and stimulates the activity of hexokinase and 
phosphofructokinase. As a result, MUC1 increases glucose uptake and lactate production 
stimulating glycolysis (63). It was also demonstrated that MUC1 occupies multiple promoters 
of genes directly involved in glucose metabolism and is responsible for an increased 
expression of glycolytic genes both in normoxia and hypoxia conditions in a hypoxia-inducible 
factor-1 alpha (HIF-1α) dependent and independent manner (64). MUC1 overexpression also 
confers cells survival advantage by blocking cell death mediated by both the intrinsic and 
extrinsic apoptotic pathways. MUC1-CD is able to bind to heat shock proteins 70 or 90 (HSP70 
or HSP90). They are translocated as a complex to the mitochondria where MUC1-CD blocks 
the loss of mitochondrial transmembrane potential abolishing apoptotic response to oxidative, 
genotoxic, hypoxic and metabolic stress (65–67). Direct interaction between p53 and MUC1-
CD was also reported in response to genotoxic stress, promoting the transcription of p53-target 
genes (68). A recent study showed that MUC1 overexpression in pancreatic cancer cells 
increases chemoresistance by upregulating multidrug resistance genes, particularly, the 
ABCC1 gene that encodes for the multidrug resistance protein 1 (MRP1) (69). The involvement 
of MUC1 in tumor cell proliferation, migration, invasion, cell survival and chemoresistance and 
its overexpression in a large number of cancers, namely, gastric, pancreatic and breast, make 
it an elective candidate for targeted therapies and big efforts are being made in this field. 
Presently, MUC1 is used as a biomarker for cancer staging and follow-up, as it is released 
from tumor cells into the circulating serum of cancer patients after cleavage of the extracellular 
domain. 
 
MUC1 and cell differentiation 
MUC1 is normally expressed at basal levels in almost all epithelial tissues and is also 
expressed in non-epithelial cells including B and T hematopoietic cells (13, 15). It is known that 
hematopoietic stem cells are enriched in MUC1 expression and its overexpression in cord 
blood cells is sufficient to increase both progenitor and long-term culture initiating cell rates 
(70). Reactive oxygen species (ROS) are critical in the regulation of self-renewal in normal 
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hematopoietic cells and MUC1 is known to regulate intracellular levels of ROS (71–74). MUC1 
is also aberrantly expressed in blasts from patients with acute myelogenous leukemia (AML), 
which is associated with unlimited self-renewal and blockage of terminal differentiation (70, 
75). Yin and colleagues described that the inhibition of MUC1-CD with the GO-203 inhibitor, a 
cell-penetrating peptide that binds to the CQC motif, induces the terminally differentiated 
myeloid phenotype in AML cell lines and primary blasts (76). This study further shows that the 
inhibition of MUC1-CD increases hydrogen peroxide and superoxide levels and depletes 
glutathione, that are known to induce terminal cell differentiation. These findings suggest the 
involvement of MUC1 in the regulation of the redox balance in AML cells while other studies 
suggested MUC1 as a good candidate target in the treatment of AML (77). In chronic myeloid 
leukemia (CML), triggered by the expression of the Bcr-Abl fusion protein (78), MUC1 is 
expressed only during the blast phase, the more aggressive stage of this disease (79). In this 
disease model, a different MUC1-CD oligomerization inhibitor, GO-201 inhibitor, is associated 
with downregulation of Bcr-Abl levels and induction of terminal cell differentiation in CML (80).  
Hikita et al. showed that undifferentiated human embryonic stem cells (hESCs) do not 
express the full length MUC1 protein but rather a low molecular weight cleaved product, 
MUC1* (14). MUC1* retains only 45 aa of the extracellular domain, harbors a growth factor 
receptor-like activity and is the predominant form of the protein expressed in breast tumor 
tissues and cell lines (81). The NM23 ligand of MUC1* in cancer cells co-localizes with 
pluripotent cells while newly differentiated stem cells express the full-length MUC1. In 
pluripotent stem cells, MUC1* functions as a growth factor receptor in a βFGF independent 
manner and may be a modulator of cell differentiation (14). More recently, the role of 
MUC1* in induced pluripotent stem (iPS) cells was also studied. Both in iPS and hES cells, 
NM23-H1 dimer binds to and dimerizes MUC1*, promoting growth and pluripotency. On the 
other hand, NM23-H1 hexamer is not capable of MUC1* dimerization inducing differentiation 
instead, which makes this complex capable of acting both as a differentiation repressor or 
inducer (82). 
It is currently accepted that a small subpopulation of cells designated cancer stem cells 
(CSCs) or tumor-initiating cells have self-renewal capacity and the ability to give rise to the 
heterogeneous cellular subpopulations identified in tumors. This subpopulation of cells is 
believed to have the exclusive ability to drive tumor formation, growth, relapse and 
chemoresistance, being also identified in an ever increasing number of human tumors (83–
86). Therefore, CSCs have been described as potentially elective targets for therapeutic 
strategies (87). More recently MUC1 has been associated with biological properties attributed 
to these cells, although the correlation between MUC1 and CSCs phenotype remains to be 
fully elucidated.  
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MUC1 was reported to be expressed in pancreatic and acute myeloid leukemia CSCs and 
to keep hESCs in an undifferentiated stage (14, 77, 88). MUC1 is upregulated by Extracellular 
Matrix Protein 1 (ECM1) which in turn increases the CSCs phenotype of breast tumor cells 
through stabilization of b-catenin protein (89). In lung cancer, using in vitro and in vivo models, 
Ham et al. reported that MUC1-CD is overexpressed in paclitaxel (PTX) resistant tumor cells. 
These authors showed that overexpression of MUC1 was involved in stemness features such 
as self-renewal, proliferation and sphere-forming ability (90). Moreover, it was reported that 
MUC1 contributes to the self-renewal capacity of breast cancer cells by acting in the NFKβ 
pathway and that the inhibition of MUC1 with MUC1-CD GO-203 inhibitor decreased this 
capacity (91). Also, in a breast cancer model, it was demonstrated that an isolated “side 
population” was highly enriched in stem/progenitor cells that show overexpression and 
hypoglycosylation of MUC1 (92). 
 
MUC1 isoforms and their role in cancer 
 Most efforts in MUC1 research have been focused on the full MUC1 protein and its role 
in cancer initiation and progression. However, MUC1 undergoes alternative splicing events 
that give rise to different isoforms with distinct biological roles (Fig. 3). 
Alternative splicing is a key process in the regulation of gene expression contributing to 
the heterogeneity of the transcriptome and the proteome and is estimated to occur in over 95% 
of all multiple-exon human genes. This mechanism generates multiple mRNAs from a single 
gene during pre-mRNA maturation and results in a variety of proteins that differ in their amino 
acid sequence. Alternative splicing has been associated with a large number of diseases, 
including cancer (93). The best characterized MUC1 isoform is the polymorphic mucin-like type 
1 transmembrane protein, MUC1/REP or MUC1/TM, which encodes the full molecule. 
However, MUC1 has different isoforms generated by alternative splicing pathways including 
exon skipping, full or partial intron retention, alternative 50 splice sites and alternative 30 splice 
sites (94). Although more than 70 isoforms have been identified so far, the full-length sequence 
has only been reported for some. 
MUC1/SEC, a secreted truncated isoform, retains the VNTR region and is devoid of the 
transmembrane and cytoplasmic regions. This isoform is secreted by different cell types, like 
breast and colon cells, benign ovarian tumors and is also present in the serum of breast cancer 
patients and in human milk (95–98).  
Recently, 78 different MUC1 isoforms were isolated from a panel of human cervical (HeLa) 
cells, breast cancer (MCF7) cells, T-cell leukemia Jurkat cells and from human activated T 
cells, being MUC1/A, MUC1/B, MUC1/C, MUC1/D, MUC1/X, MUC1/Y and MUC1/ZD the more 
abundant ones (94). This study identified exon 2, which contains the VNTR region, as the most 
skipped exon among all the different isoforms using the same 50 splice site and variable 30 
Chapter 5 | Reflections on MUC1 glycoprotein: the hidden potential of isoforms in carcinogenesis  
95 
 
splice sites. The authors point several different reasons for this to occur, namely, the large size 
of this exon which can be as high as 6200 bp; the presence of core splicing signals such as 
the 50 splice site, the 30 splice site and the branch point site in the VNTR sequence; the 
presence of cis-regulatory elements at the junction of the repeats that have been described as 
intron splice; the existence of Nova splicing factor binding sites (YCAY, with Y being any 
pyrimidine) in each repeat, which can result in a blockage of exon inclusion when bound by 
Nova. On the other hand, MUC1-CD region remains unchanged in almost all MUC1 short 
isoforms, allowing them to keep the important signaling function (94).  
MUC1/A, MUC1/B, MUC1/C and MUC1/D encode a “full-length” MUC1 having a fixed 
splice donor site near the 50 end of intron 1 and variable splice acceptor sites near the 30 and 
50 ends of intron I and exon 2, respectively. MUC1/A retains 27 bp of intron I without causing 
a reading frameshift while MUC1/B has intron I completely excised. MUC1/C and MUC1/D 
show excision of portions of exon 2, 9 bp and 35 bp respectively, keeping the reading frame 
(99, 100). MUC1/A was initially described in thyroid carcinoma tissues, is usually associated 
with malignancy and is expressed preferentially in ovarian cancer when compared to benign 
tumors (97, 101). On the other hand, MUC1/B was described as having significantly higher 
expression in normal tissue and is associated with better prognosis in tumors of the esophagus 
(102). However, there are few reports describing the expression pro-file of MUC1/A and 
MUC1/B in tumors which hampers an accurate evaluation of the relevance of these two splice 
variants in carcinogenesis.  
MUC1/Y, MUC1/X and MUC1/ZD splice variants arise from a fixed splice donor at the 50 
end of exon 2 and different splice acceptor sites around the 30 end of exon 2 resulting in MUC1 
isoforms that lack the VNTR region but retain the transmembrane and cytoplasmic domains. 
MUC1/Y, an uncleaved splice variant, does not exhibit mucin-like features. However, it is 
expressed by diverse human secretory epithelial tumors, being undetectable in the adjacent 
normal tissue. It was also shown to be involved in tumor initiation and progression, in vivo, in 
breast cancer (103–106). It was described that MUC1/Y undergoes tyrosine/serine 
phosphorylation being potentially able to interact with proteins containing a SH2 domain, such 
as Grb2, triggering a cell signaling cascade and functioning in a similar way to cytokine 
receptors (104, 107). MUC1/SEC is capable of binding to MUC1/Y in a region homologous to 
the ligand binding sites of cytokine receptors, inducing its phosphorylation and stimulating cell 
signaling pathways (104). MUC1/Y was also shown to be overexpressed in ovarian and 
prostate cancer, being also associated with breast cancer (108–110). 
MUC1/X and MUC1/ZD were also associated with malignant ovarian tumors (97). 
MUC1/X, like MUC1/Y, misses the VNTR region but has a different acceptor site 18aa 
upstream to MUC1/Y. It is highly expressed in cervical and ovarian cancer cells and contrary 
to MUC1/Y this isoform undergoes proteolytic cleavage (106, 108, 111, 112). MUC1/ZD also 
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lacks the VNTR region but is comprised of a unique C-terminal sequence of 43 aa resulting 
from a shift in the reading frame (106). 
More recently, a truncated genomic fragment of human MUC1 was shown to induce 
epithelial to mesenchymal transition in mammary mouse cells (113). In addition, a MUC1 
transmembrane cleaved form (MUC1*) was reported to have an important role in 
chemoresistance to standard chemotherapy agents (114) as well as to be an accurate marker 
of pluripotency in human embryonic stem cells while full-length MUC1 is present in newly 
differentiated stem cells as mentioned before (14). This isoform contains only 45 aa of the 
MUC1 extracellular domain, lacking the VNTR region. 
MUC1/S2 isoform was identified in human cervical (HeLa) and breast cancer (MCF7) cell 
lines and is absent in T-cell leukemia Jurkat cells and human activated T cells (94). This splice 
variant has a retention of 27 bp of intron I, excision of 659 bp from exon 2 and total excision of 
exons 3, 4 and 5 lacking the transmembrane domain and cleavage site of the SEA domain. 
We have investigated the role of MUC1/S2 isoform in a pancreatic cancer model. For that, we 
used a transformed hTERT-THPNE (THPNE) cell line derived from a non-tumorigenic 
epithelial pancreatic duct and immortalized with the catalytic subunit of telomerase (115). 
THPNE cell line was generated, as previously described, by sequential retroviral mutant K-
Ras (G12D), E6/E7, and SV40 small t antigen transduction in order to mimic some of the 
oncogenic alterations present in the current accepted pancreatic cancer progression model 
(115, 116). Transfection of MUC1/S2 sequence (AY327584) into the THPNE cell line allowed 
the observation that MUC1/S2 expression is mostly restricted to the cytoplasm and to a lesser 
extent to cells nuclei. MUC1/S2 led to increased invasion of these pancreatic cancer cells and 
interestingly, it still interacted with p53 despite not having the full protein structure, which can 
indicate a role of this isoform in signaling pathways (unpublished data). Further studies are 
necessary to disclose the complete role of this MUC1 splice variant in pancreatic cancer. 
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Fig. 3. Representation of MUC1 gene with respective protein domains and different mRNA splice 
variants. MUC1 gene comprises seven exons (E1-E7) and six introns (I-VI). The respective protein 
domains encoded by each exon region are represented above the exon. The mRNA of different splice 
variants is schematized. MUC1/A, MUC1/B, MUC1/C and MUC1/D represent the four main variants and 
have distinct 30 splice acceptor sites in exon 2. MUC1/X, MUC1/Y and MUC1/ZD splice variants 
completely lack the VNTR region. MUC1/S2, besides the VNTRs excision lacks exons 3, 4 and 5. 
MUC1/SEC splice variant, which retains the VNTR region and has a premature stop codon within intron 
II is also represented. 
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Conclusions and Future challenges 
MUC1 has been associated with oncogenic events in many epithelial tumor models. The 
full extent of such involvement has been investigated in different biological contexts including 
tumor cell survival, proliferation, differentiation, migration and invasion. The newly identified 
MUC1 functions expose the ubiquitous role of this mucin in the carcinogenesis process, both 
in initiation as well as in progression and metastasis. The growing scenario of a multi-task 
MUC1 reflects the structural and functional complexity of the molecule, nonetheless the 
identification of MUC1 functions that drive the neoplastic transformation and those that derived 
from it, remains rather challenging. 
The available evidence collected so far remains limited to answer questions about MUC1 
overexpression and abnormal glycosylation in tumor cells, or the relevance of MUC1 in 
oncogenic signaling cascades and transcriptional regulatory networks. More recently, insights 
about MUC1-mediated chemoresistance, tumor cell metabolism, epithelial to mesenchymal 
transition (EMT) and stem cells phenotype further increase the current challenges that both 
basic and clinical researchers are facing. Addressing these questions will be essential to 
progress on the fully comprehension of this molecule impact on cancer phenotype and to 
expand the panel of new MUC1-based clinical approaches.  
MUC1 is an elective target for cancer immunotherapy due to the high protein expression 
and abnormal forms associated with malignancy. A diverse assortment of MUC1-based 
therapeutic strategies have been investigated lately, encompassing monoclonal antibodies 
(MAb) and vaccines, aptamers and nanoparticles (117, 118). The Mab based therapies and 
vaccines have been previously focused on MUC1-N VNTR aberrant glycosylation, but lately a 
progressive shift occurred and the new generation of MAb and vaccines is targeted to MUC1-
C. The cytoplasmic region of MUC1 is also the focus of aptamers designed to inhibit 
dimerization and phosphorylation motifs present in this region. Clinical trials are currently 
evaluating and optimizing these new therapies in different tumor models (119–121). Similarly, 
MUC1 has been found to be a useful biomarker for prognostic and follow-up, due to the 
presence of MUC1 in the membrane of circulating tumor cells or in the serum of cancer patients 
(122, 123). 
Understanding the pattern of expression, subcellular localization, biological functions and 
diagnostic/prognostic value of the different MUC1 isoforms is an essential step to clarify MUC1 
role in the different hallmarks of cancer. Despite a few reports that revealed the existence of a 
vast amount of different MUC1 splice variants, most of the previous studies addressing MUC1 
isoforms were PCR technology based and thus very unspecific on discriminating MUC1 splice 
variants that share gene sequences. The evidences gathered so far reinforce the relevance 
and ubiquity of MUC1 in neoplastic phenomena; still it urges to develop new tools (e.g., 
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antibodies) and mobilize the current available technologies (e.g., next generation sequencing) 
to disclose the full spectrum of MUC1 isoforms in malignant cells. Our group has been focused 
and will pursue the study of MUC1 variants relevance for the biology of normal and pancreatic 
tumor cells using engineered in vitro models that mimic the pancreatic carcinogenesis. 
The polymorphic nature of MUC1 molecule, enhanced by the tumor-specific alterations, 
and the vast underlying transcriptome, encompasses a unique potential waiting to be 
translated into innovative therapies of personalized medicine. 
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Pancreatic cancer remains a dismal disease for the vast majority of the patients 
representing a huge challenge worldwide both in basic research and in the clinical field. 
Despite the efforts, conventional therapeutic approaches that include surgery, radiation, 
chemotherapy and even a combination of these three, have shown little impact on the 
development of the disease. Facing this, the understanding of pancreatic cancer molecular 
biology to address a better diagnosis, prevention and treatment is crucial. In this study, we 
aimed to determine the involvement of MUC1 in the CSC phenotype and to investigate 
biological functions of MUC1 splice variants in pancreatic carcinogenesis, two considerably 
underdeveloped fields in pancreatic carcinogenesis. 
Alterations in glycans profile and in mucin expression levels are common amongst 
adenocarcinomas including pancreatic. MUC1, the best characterized mucin, is overexpressed 
in around 80% of all PC showing a different glycosylation profile and cell expression 
distribution. Despite MUC1 involvement in tumor progression, metastasis and poor prognosis 
being well characterized and extensively revised, its role in carcinogenic initiation is not fully 
known. A recent study reported that a transmembrane cleaved form of this protein (MUC1*) is 
expressed in pluripotent human embryonic stem cells (hESCs) working as a growth factor 
receptor. This leads to increased proliferation and prevents cells from differentiation upon 
binding to a metastasis associated protein, NM23-H1 (Hikita et al. 2008, Mahanta et al. 2008). 
More recently, Mukherjee P. and colleagues showed that a new monoclonal antibody against 
the tumor-associated MUC1 protein was able to identify CSCs in patients with PC (Curry et al. 
2013). 
The reported associations between MUC1 and CSCs led us to investigate the potential 
contribution of MUC1 to oncogenic signaling pathways in these cells. Several markers have 
been used to identify and isolate CSCs from different tumor types including colon, prostate, 
breast and pancreas (Al-Hajj et al. 2003, Collins et al. 2005, Dalerba et al. 2007, Hermann et 
al. 2007). In pancreas, the markers used for CSC isolation were the combination of CD44+ 
CD24+ ESA+ cell surface markers and CD133 surface markers (Hermann et al. 2007, Li et al. 
2007, Moriyama et al. 2010). Based on these markers, the subpopulations isolated showed a 
higher tumorigenic and self-renewal capacity as well as higher resistance to standard 
chemotherapy and a close relationship with the metastatic phenotype (Hermann et al. 2007, 
Moriyama et al. 2010). 
Human CD133 is a 120kDa cholesterol-interacting pentaspan-transmembrane 
glycoprotein, expressed in plasma membrane protrusions, also known as Prominin-1. CD133 
protein was initially described as a cell surface antigen specific of hematopoietic stem and 
progenitor cells as well as bone marrow-derived circulating endothelial progenitors involved in 
angiogenesis, inflammation and tissue regeneration (Asahara et al. 1997, Miraglia et al. 1997, 
Yin et al. 1997, Shaked et al. 2006). Although the involvement of CD133 in the maintenance 
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of stem cells properties has been previously reported, its biological function remains 
controversial and under debate (Marzesco et al. 2005, Sgambato et al. 2010). However, some 
reports showed a correlation of this marker with poor PC prognosis and other cancer types 
(Kojima et al. 2008, Maeda et al. 2008, Chen et al. 2013, Okamoto et al. 2013). In pancreas, 
it was described that spontaneous LSL-KrasG12D/+; LSL-Trp53R172H/+; Pdx-1-Cre (KPC) mouse 
model, an aggressive model with 100% penetrance and about 6 months survival, has 
approximately 7–8% of CD133+ cells that showed an increased expression of prosurvival and 
proinvasive proteins when compared with CD133- cells (Hingorani et al. 2005, Banerjee et al. 
2014). In CSCs, namely in pancreatic CSCs, it is know that several canonical signaling 
pathways involved in self-renewal, tumor growth, invasion, metastization and chemoresistance 
are altered and it is argued that the inefficiency of current therapies is due to the failure of 
eradicating this subpopulation of cells (Castellanos et al. 2013). Overexpression of CD133 in 
a pancreatic cancer cell line showed an increase in CSC phenotype and upregulation of 
several genes related with “stemness” such as NANOG, MYC and SOX2, among others 
(Nomura et al. 2015). Hence, as a first objective of this thesis we evaluated the involvement of 
MUC1 and its signaling partners in the phenotype of pancreatic CSCs in order to better 
understand the mechanisms that regulate the specific biological properties of this 
subpopulation of cells. With this purpose, we isolated pancreatic CSCs, using a well-
established magnetic cell sorting (MACs) method, based on the CD133 surface marker assay 
and using a moderately differentiated PDAC cell line, HPAF-II. This cellular model, derived 
from the ascitic fluid of a patient with PDAC, offers the advantage of being a low-passage cell 
line that more accurately mimics the primary tumor (Metzgar et al. 1982). Our results 
demonstrated that the isolated CD133+ cell subpopulation show well defined features of CSCs 
(tumorigenicity, tumor phenotype recapitulation) and concomitantly have increased expression 
of MUC1. MUC1 is involved in cell signaling-transduction events mostly through MUC1-CD 
phosphorylation. MUC1-CD encompasses 72 amino acids that comprise several serine and 
tyrosine residues which can be extensively phosphorylated by different proteins with SH2 
domains, such as PKCδ, GSK-3β and EGFR (Pandey et al. 1995, Quin and McGuckin 2000, 
Li et al. 2001). Changes in the phosphorylation status of MUC1-CD modulate its affinity to 
interact with mediators of signal transduction, triggering signaling pathways and leading to 
changes in gene expression and consequently, cell phenotype (Ren et al. 2002, Wei et al. 
2007). One of these mediators is β-catenin, which binds directly to MUC1-CD SAGNGGSSLS 
motif in the armadillo repeats (Yamamoto et al. 1997, Huang et al. 2003). 
In this work, we characterized the expression of EGFR, PKCδ, GSK-3β and GRB2 kinases 
that are known to be involved in MUC1 signaling pathways. In the CD133+ cells subpopulation, 
an increased expression of EGFR and PKCδ was observed while GSK-3β expression was 
decreased. It is known that MUC1-CD phosphorylation by EGFR and PKCδ promotes 
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interactions between β-catenin and MUC1, while phosphorylation by GSK3β leads to a 
decrease in this association (Li et al. 1998, Schroeder et al. 2001). Indeed, we were also able 
to identify an increased MUC1-CD/β-catenin interaction in the CD133+ cell subpopulation 
despite unchanged levels of steady state β-catenin levels in these cells. This increased 
interaction is observed both in the CD133+ cell subpopulation and derived xenograft. It is 
known that MUC1/β-catenin complex is involved in several tumorigenic processes being 
responsible for the activation of the Wnt/β-catenin signaling pathway. In epithelial cells, β-
catenin is a crucial element of the adherens junction that associates cadherin adhesion 
molecules located at the cell surface to the actin cytoskeleton. MUC1-CD/β-catenin interaction 
leads to a decrease in the capacity of β-catenin to interact with E-cadherin at the adherens 
junctions and this decrease plays an important role in tumor invasion since it results in loss of 
cell-cell adhesion (Yuan et al. 2007). Furthermore, this MUC1-CD/β-catenin complex 
contributes to β-catenin stabilization by blocking GSK3β-mediated phosphorylation and 
consequently its degradation in the proteasome (Huang et al. 2005). MUC1-CD/β-catenin is 
translocated to the nucleus, which has been observed in MUC1-transfected human pancreatic 
cancer cell lines and rat fibroblasts, and can enhance the activity of β-catenin in association 
with TCF/LEF transcription factors, promoting cell proliferation and survival through 
upregulation of Wnt target gene transcription (Behrens et al. 1996, Huang et al. 2003, Li et al. 
2003, Wen et al. 2003, Baldus et al. 2004). More recently, MUC1-CD/β-catenin complex was 
associated with a metastatic gene expression signature and an EMT phenotype of tumor cells 
(Gnemmi et al. 2014). In this work, CD133+ tumor xenografts showed the presence of MUC1-
CD/β-catenin interactions in the nuclei of the cells, where they presumably bind to transcription 
factors and activate transcription of genes involved in cell proliferation and survival such as 
cyclin D1 (Huang et al. 2003, Lamb et al. 2003, Udhayakumar et al. 2007). We further showed, 
for the first time, that pancreatic CD133+ cells exhibit enhanced MUC1 expression and 
associated signaling partners. CD133 and MUC1 expression are associated with a more 
aggressive tumor phenotype, in part through enhanced MUC1-CD/β-catenin interactions, and 
this may contribute to explain the behavior of pancreatic CSCs. 
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Figure 1. Proposed model for MUC1 signaling partners interactions in the pancreatic 
CSCs subpopulation. In this model we propose a mechanism for the phenotype of the pancreatic 
CSC subpopulation through MUC1 signaling pathway. In the CSCs subpopulation (CD133+ cells), higher 
levels of EGFR and PKCδ kinases lead to an increase in MUC1-CD phosphorylation which promotes 
MUC1-CD/β-catenin interaction. MUC1-CD/β-catenin interaction together with the decrease in GSK3β-
mediated phosphorylation stabilizes β-catenin by blocking its degradation in the proteasome. 
Furthermore, this interaction decreases E-cadherin/β-catenin complex formation at the cell membrane 
that results in loss of cell-cell adhesion. In the cytoplasm, MUC1-CD/β-catenin complex is able to 
translocate to the nucleus where it binds to TCF/LEF transcription factors promoting cell proliferation 
and survival through Wnt/β-catenin signaling pathway activation and therefore contributing to the 
tumorigenic potential of pancreatic CSCs. The canonical interactions depicted in the CD133low cell 
subpopulation are responsible for the absence of malignance. 
 
MUC1 structure has been extensively studied since its cloning in 1990. Nevertheless, 
much remains unknown about the alternative splicing events, and despite more than 70 
isoforms have now been described, their specific biological functions and expression profiles 
remain to be elucidated (Zhang et al. 2013). Alternative splicing events can increase the cell 
proteome and has been considered more reliable in discriminating tumor from normal tissue 
than transcription-level differences (Li et al. 2006, Zhang and Gish 2006). MUC1 gene 
comprises seven exons and six introns and a variety of isoforms can be generated by 
alternative splicing, intron retention and exon skipping, being exon 2 the most skipped one 
(Zhang et al. 2013). Therefore, it is crucial to develop knowledge about the specific expression 
pattern and biological relevance in normal and neoplastic context. Among the differences of 
expression between different tumors it is important to refer the reported function of MUC1/Y in 
cell signaling through its phosphorylation, working in a similar way to cytokine receptors 
(Baruch et al. 1999). It is also important to highlight the described role of MUC1 truncated 
fragment MUC1* in the induction of EMT, in resistance to standard chemotherapeutic agents 
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and its potential of being an accurate marker of pluripotency in human embryonic stem cells 
(Hikita et al. 2008, Fessler et al. 2009, Horn et al. 2009). The lack of a clear understanding 
about the expression and the biological function of all the described splice variants is mostly 
due to the absence of specific antibodies. 
In this part of the work the objective was to study the relevance of MUC1/S2 splice variant 
in pancreatic carcinogenesis. This splice variant was identified in human cervical (HeLa) and 
breast cancer (MCF7) cell lines and is absent in T-cell leukemia Jurkat cells and human 
activated T cells (Zhang et al. 2013). MUC1/S2 has a retention of 27bp of intron I and excision 
of 659bp from exon 2 and total excision of exons 3, 4 and 5, lacking the transmembrane domain 
and cleavage site of the SEA domain. There are no studies about the biological function of this 
splice variant. A cell line immortalized with the catalytic subunit of telomerase was used, as 
described by Campbell and colleagues, transformed by sequential retroviral mutant K-Ras 
(G12D), E6/E7, and SV40 small t antigen transduction cell line, in order to provide some of the 
oncogenic insults present in the currently accepted pancreatic cancer progression model 
(Hruban et al. 2000, Campbell et al. 2008). Transduction with MUC1/S2 and MOCK was 
performed through lentivirus system and stable clones established by limited dilutions. We 
evaluated the expression pattern of the MUC1/S2 splice variant and its impact in proliferation, 
migration and invasion of the generated cells. Moreover, we evaluated the subcellular 
localization of MUC1/S2 and its interaction with p53 protein to evaluate its possible involvement 
in cell signaling. MUC1/S2 lacks the transmembrane domain making it unlikely to be activated 
in response to the external environment as it occurs when MUC1 is localized in the membrane 
(Schroeder et al. 2001). Despite the expression of this isoform being mostly restricted to the 
cytoplasm it was also possible to observe expression in the nuclei of the cells. 
MUC1/S2 localization in the nuclei indicates that although not having the cleavage region, 
MUC1/S2 is capable of translocation to the nuclei which points towards its participation in 
the modulation of transcriptional events that are involved in malignant progression, namely, 
invasion and metastasis formation in response to, for example, Wnt/β-catenin or STAT 
pathways activation (Ren et al. 2002, Gao et al. 2009). In the co-localization assay, this isoform 
was identified as being present in the mitochondria, golgi apparatus, endoplasmic reticulum 
and lysosomes. The endoplasmic reticulum, where it was possible to observe the majority of 
the protein in the studied compartments, has a central role in protein biosynthesis, determining 
the correct folding of a protein which affects both its function and cellular localization and even 
if the protein will be secreted. Post-translational modifications, such as N-glycosylation, are 
processes that take place in the ER and can be occurring to MUC1/S2, explaining the observed 
results. Due to the relevance of the mitochondria in apoptosis, and the relevance of this 
process in carcinogenesis, it is important to study MUC1/S2 presence in this subcellular 
compartment deeply, where it was also possible to identify co-localization. 
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We also evaluated the possible impact of MUC1/S2 in the invasive phenotype of the 
generated cells. Indeed, MUC1/S2 leads to an increased invasion of pancreatic cancer cells. 
The involvement of full MUC1 in invasion is documented and one of the described mechanisms 
shows that once translocated to the nucleus, MUC1 is capable of repressing E-cadherin 
expression and induce expression of EMT inducers such as Snail and Slug (Roy et al. 2011). 
Excitingly, we identified for the first time an interaction between MUC1/S2 isoform and p53 
protein, which is known to be involved in MUC1 signaling. p53 is a major tumor suppressor 
gene involved in DNA repair, apoptosis, cell cycle arrest among others and is mutated in over 
50% of human cancers (Lane and Levine 2010). We observed an interaction between 
MUC1/S2 and p53, mostly in the cytoplasm. This interaction was described, in the nucleus, as 
contributing to the regulation of p53-responsive genes, namely, activation of p21 and 
repression of Bax transcription, two proteins involved in cell-cycle progression and apoptosis 
(Wei et al. 2005). There are no studies showing the relevance of the interaction between MUC1 
and p53 in the cytoplasm and further studies are warranted to confirm this interaction and if it 
plays a role in carcinogenesis.  
In the review, we characterized in detail the role of MUC1 in carcinogenesis, highlighting 
recent findings in cell differentiation and uncovering new evidences of the involvement of 
MUC1 isoforms in the malignant phenotype. Until now, MUC1 has been found to be a useful 
biomarker for cancer staging follow-up and there is growing evidence of MUC1 pivotal role on 
tumorigenesis, remaining to be fulfilled the promise to be used as a target therapy. Hence, 
efforts in understanding more unexplored fields such as MUC1 involvement in cell 
differentiation and the putative discriminatory power of different isoforms in disease staging 
and biological phenotype remain essential.      
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Pancreatic cancer is one of the most aggressive cancers with 5-year survival rates 
remaining stable in decades and mortality rates being almost the same as incidence. Early 
diagnosis and new therapeutic targets to overcome resistance mechanisms remain crucial 
challenges for both researchers and clinicians. 
In this work we aimed to better understand the involvement of the MUC1 glycoprotein in 
the CSC phenotype and to investigate the biological function of MUC1 splice variants in 
pancreatic carcinogenesis. 
 
The main conclusions of this thesis are: 
 
We showed, for the first time, that putative pancreatic CSC (CD133+) have increased 
expression of MUC1 and associated signaling partners. CD133 and MUC1 expression are 
associated with a more aggressive tumor phenotype, in part through production of enhanced 
MUC1-CD/β-catenin interactions, and this may explain to some extent the behavior of 
pancreatic CSCs. 
We validated the use of an in vitro model based on a transformed pancreatic cell line 
transduced with a MUC1 splice variant to study its relevance in pancreatic carcinogenesis. 
Excitingly, it was identified for the first time an interaction between MUC1/S2 isoform and p53 
protein. The expression of the studied MUC1/S2 splice variant is mostly restricted to the 
cytoplasm, however, expression in the nucleus of the cell was also possible to observe. 
Moreover, its distribution profile included important organelles in cell dynamics such as the 
endoplasmic reticulum and mitochondria. These findings, together with the observed increased 
invasive phenotype of the MUC1/S2 cells, suggest that MUC1 splice variants might 
encompass a plethora of biological functions in the neoplastic pancreatic cell.  
 
The results found in this research work reinforce the importance of MUC1 in the 
tumorigenic behavior of pancreatic cancer cells, more specifically its role in pancreatic cancer 
stem cells phenotype. Furthermore, the demonstration that a specific MUC1 splice variant is 
associated with the acquisition of cancer cell hallmarks, will add these molecules to the 
scenario of elective targets to address both early diagnosis and therapy of pancreatic tumors.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
